Protein binding fragments of gravin

Abstract

The present invention generally relates to protein binding fragments of gravin and polynucleotides encoding these fragments. The protein binding fragments include fragments which bind to the Type II regulatory subunit of cAMP-dependent protein kinase or protein kinase C. This invention further provides antibodies to the protein binding fragments and assays for identifying compounds which modulate the binding of gravin to the binding protein.

Description

FIELD OF THE INVENTION

The present invention relates generally to proteins that maintain the subcellular localization of kinases. More specifically, this invention relates to polypeptide fragments of a protein, gravin, which binds to a regulatory subunit of cAMP-dependent protein kinase or to protein kinase C. The invention also relates to methods of modulating the interaction of gravin and its binding partners.

BACKGROUND OF THE INVENTION

Protein kinases are ubiquitous enzymes expressed in all eukaryotic cells and are involved in cellular responses to physiological stimuli. Protein kinases attach phosphate groups to substrate proteins. Cyclic-AMP (cAMP) dependent protein kinase (PKA) is an enzyme with broad substrate specificity which phosphorylates substrate proteins in response to cAMP. Protein kinase C (PKC) is an enzyme which phosphorylates substrate proteins in response to intracellular Ca.sup.2+ and phospholipid.

Many hormones act through common signal transduction pathways that generate the intracellular second messenger cAMP. The predominant action of cAMP is to activate a PKA by binding to the regulatory subunit (R) dimer of the holoenzyine thereby releasing the catalytic (C) subunit. Free C subunit potentiates hormonal responses by phosphorylating substrate proteins near the site of kinase activation.

Two classes of the R subunit have been identified; RI and RII subunits which respectively form the type I and type II PKA holoenzymes. The subcellular distributions of PKA isoforms appear to be distinct. The RI isoforms (RI.alpha. and RI.beta.) are reported to be predominantly cytoplasmic and are excluded from the nuclear compartment, whereas up to 75% of the RII isoforms (RII.alpha. or RII.beta.) are particulate and associate with the plasma membrane, cytoskeletal components, secretory granules, the golgi apparatus, centrosomes and/or possibly nuclei. (RII.alpha. or RII.beta.) are particulate and associate with the plasma membrane, cytoskeletal components, secretory granules, the golgi apparatus, centrosomes and/or possibly nuclei.

Intracellular transduction of signals from the plasma membrane to specific subcellular compartments is a complex and highly regulated series of events which control essential physiological processes. An example of signaling pathway involvment are essential in maintaining cellular homeostasis appears in Hunter, Cell, 80:225-236 (1995) where it was shown that many transforming oncogenes encode signal transduction components such as low molecular weight G proteins, protein kinases, or phosphatases. Phosphatases remove phosphate groups from proteins or other compounds. Kinase and phosphatase activities thus control intracellular signal transduction by phosphorylating and dephosphorylating substrate molecules. Now that many genes encoding these proteins have been identified, research emphasis has begun to focus on how these enzymes interface to control cellular events. A critical element in this operation is the subcellular location of each signaling enzyme. For example, Newton, Current Biology, 6:806-809 (1996) showed that the correct intracellular targeting of kinases and phosphatases directs these enzymes to their preferred substrates and reduces indiscriminate background phosphorylation and dephosphorylation.

Kinase and phosphatase targeting is achieved through association with targeting proteins or subunits [reviewed by Faux and Scott, TIBS, 21:312-315 (1996b)]. For example, tyrosine kinase (PTK) and tyrosine phosphatase (PTPase) activity are coupled to downstream cytoplasmic enzymes through adaptor proteins that contain SH2 and SH3 domains. SH2 domains recognize certain phosphotyrosyl residues and SH3 domains bind to a PXXP motif found in some kinases and phosphatases. Modular adaptor proteins like Grb2, p85, IRS-1, Crk and Nck comprise a single SH2 domain that recognizes phosphotyrosyl residues of signalling enzymes and two SH3 domains that bind to the PXXP motif on a separate set of target proteins. Similarly, many phospholipases, kinases, phosphatases and heterotrimeric G-proteins are targeted by specific membrane-targeting motifs such as the LIM, C2, pleckstrin homology and lipid anchoring domains [Gill, Structure, 3:1285-1289 (1995); Newton, Current Biology, 5:973-976 (1995)]. Through these interactions, signaling complexes assemble around receptor kinases or scaffold proteins to mediate cellular processes including hormone signaling events and immune cell function [Harrison et al., TIBS, 20:1213-1221 (1995)].

Until recently, second messenger-stimulated kinases and phosphatases were thought to be localized through association with individual targeting proteins. For example, three classes of phosphatase targeting subunits have been identified which are specific for protein phosphatase I [Chen et al. FEBS Letters, 356:51-55 (1994)]; protein phosphatase 2A [Csortos et al., J. Biol. Chem., 271:2578-2588 (1996)]; or protein phosphatase 2B [Shibasaki et al., Nature, 382:370-373 (1996)]. Likewise, three classes of PKC targeting proteins have been identified in Chapline et al., J. Biol. Chem. 268:6858-6861 (1993); Mochly-Rosen, 1995; and Staudinger et al., J. Cell Biol., 128:263-271 (1995). Compartmentalization of PKA is achieved through interaction of the R subunits with a functionally related family of thirty or so A-Kinase Anchoring Proteins, called AKAPs [reviewed in Scott and McCartney, Molecular Endocrinology, 8:5-13 (1994)]. The present invention contemplates that anchoring proteins confer specificity on serine/threonine kinases and phosphatases by directing these enzymes to discrete subcellular sites where they have restricted access to certain substrates and are optimally positioned to respond to fluctuations in the levels of second messengers.

A variation on this theme was reported in the recent identification of multivalent binding proteins that coordinate the location of serine/threonine kinase and phosphatase signaling complexes. For example, Herskowitz, Cell, 80:187-197 (1995) showed that the pheromone mating response in yeast is initiated through a G-protein linked receptor that activates a yeast MAP kinase cascade. This process proceeds efficiently because each enzyme in the cascade is associated with a scaffold protein called sterile 5 (STE 5) [Choi et al., Cell, 78:499-512, (1994)]. Clustering of successive members in the MAP kinase cascade allows for the tight regulation of the pathway and prevents "cross-talk" between the six functionally distinct MAP kinase modules in yeast [Herskowitz et al., 1995]. Another example of a multivalent binding protein is AKAP79 which targets PKA, PKC and protein phosphatase 2B at the postsynaptic densities of mammalian synapses [Klauck et al., Science, 271:1589-1592 (1996); Coghlan, et al., (1995b). The structure of AKAP79 is modular and resembles STE 5. Deletion analysis, peptide studies and co-precipitation studies of AKAP79 and STE5 have demonstrated that enzymes bind to distinct regions of the anchoring protein [Klauck et al., 1996]. Targeting of the AKAP79 signaling complex to the postsynaptic densities suggests a model for reversible phosphorylation in which the opposing effects of kinase and phosphatase action are co-localized by a common anchoring protein [Coghlan et al., Advances in Protein Phosphatases, 6:51-61 (1995a)].

AKAPs have been identified in a variety of organisms. At least seven proteins that bind the regulatory subunit of PKA in Aplysia californica, a marine invertebrate, have been identified [Cheley et al., J. Biol. Chem., 269:2911-2920 (1994)]. One of these proteins is enriched in crude membrane fractions and taxol-stabilized microtubules and may thus anchor microtubules to the cell membrane as well as bind PKA. A mammalian AKAP microtubule-associated protein 2 (MAP2) attaches PKA to the cytoskeleton [DeCamilli et al., J. Cell Biol., 103:189-203 (1986)]. The PKA-binding site on MAP2 is a 31-residue peptide in the amino-terminal region of the MAP2 molecule [Rubino et al., Neuron, 3:631-638 (1989)].

To date, a number of AKAPs have been identified which apparently bind PKA by a common secondary structure motif that includes an amphipathic helix region [Scott and McCartney, 1994]. Binding of PKA to most, if not all, identified AKAPs can be blocked in the presence of a peptide (Ht31) (SEQ ID NO: 8) that mimics the common secondary structure, while a mutant Ht31peptide containing a single amino acid substitution (SEQ ID NO: 18) that disrupts the secondary structure of the peptide has no effect on PKA/AKAP binding [Carr et al, J. Biol. Chem., 266:14188-14192 (1991)]. Even though PKA/AKAP interaction is effected by a common secondary structure, AKAPs (or homologous AKAPs found in different species) generally have unique primary structure as is evidenced by the growing number of AKAPs that have been identified in a variety of organisms. The unique structure in each anchoring protein confers specificity on a kinase by targeting an AKAP signalling complex to specific intracellular locations.

Chapline and co-workers recently reported the cloning of a PKC binding protein identified as "clone 72" [Chapline et al., J. Biol. Chem., 271:6417-6422 (1996)]. Interestingly, Clone 72 was shown to have substantial homology to a mitogenic regulatory gene identified as "clone 322" [Lin et al., Mol. Cell. Biol., 15:2754-2762 (1995)]. Clone 322 was identified as being the same molecule identified as "SSeCKS" in Lin, et al., J. Biol. Chem. 271:28340-28348 (1996). Clone 322 was shown to be down-regulated in oncogene (e.g., src, ras, fos and myc) transformed cells and thus appears to be a tumor suppressor gene.

Also of interest to the invention is Myasthenia gravis (MG), a disease of neuromuscular transmission characterized by weakness and rapid fatigability of the muscles. It is believed that MG is an autoimmune disease in which the patient develops antibodies to the nicotinic acetylcholine receptor. The nicotinic acetylcholine receptor controls a cation channel in response to binding of acetylcholine. In addition, development of autoantibodies to other cytoskeletal antigens including alpha actinin, actin, filamin and vinculin is observed in the MG patient. The muscle weakness appears to be caused by a failure of the nicotinic acetylcholine receptor as the autoantibodies apparently participate in destruction of the nicotinic acetylcholine receptors.

A previously unknown MG antigen, gravin, was identified by expression screening of a cDNA library with serum from a patient suffering from MG [Gordon et al., J. Clin. Invest., 90:992-999 (1992)]. Gordon, et al. disclosed amino acid sequences disclosing 306 C-terminal amino acid residues of gravin and the corresponding polynucleotide. Gravin was shown to be expressed on the cell cortex and was also shown to be expressed in migratory cells such as fibroblasts and neurons, but not in stationary cells such as epithelial cells. In addition, gravin was found to be expressed in adherent cells, but not in non-adherent cells. Therefore, gravin was postulated to play a role in cell migration and/or cellular adhesion [Grove et al., Anat. Rec., 239:231-242 (1994)].

There continues to exist a need in the art for further insights into the nature, function,and distribution of anchoring proteins and the role of anchoring proteins in myasthenia gravis.

SUMMARY OF THE INVENTION

This present invention is based on the discovery that gravin is a kinase anchoring protein that binds to the type II regulatory subunits of PKA and to PKC. The complete amino acid sequence of gravin is provided herein. In binding to protein kinases, gravin localizes kinases to a specific subcellular region(s) and may regulate the function of the kinases and thereby control cellular signalling.

In one aspect, the present invention provides a gravin polypeptide fragment that binds to the type II regulatory subunit of PKA. Preferably, the polypeptide fragment comprises amino acid residues 1526-1582 (SEQ ID NO: 1) of gravin. More preferably, the polypeptide fragment comprises amino acid residues 1537-1563 (SEQ ID NO: 2) of gravin.

In another aspect, the present invention provides a polypeptide fragment that binds to PKC. Preferably, the polypeptide fragment comprises amino acid residues 265-556 (SEQ ID NO: 3) of gravin.

Yet another aspect of this invention provides polypeptide analogs of such fragments. Analogs are fragments in which additions, substitutions, including conservative substitutions, or deletions of amino acid residues have been made in order to increase or decrease the binding affinity of the analog fragment for a protein kinase. These analogs of gravin may be useful for modulating (i.e., blocking, inhibiting, or stimulating) the interaction between gravin and the kinase.

The polypeptides of the present invention are synthesized in solution or on a solid support in accordance with conventional techniques as described in Stewart and Young, Solid Phase Peptide Synthesis, 2nd ed., Pierce Chemical Company, (1984) or Tam et at., J. Am. Chem. Soc., 105:6442 (1983), both of which are incorporated herein by reference.

The polypeptides of this invention may be modified to facilitate passage into the cell, such as by conjugation to a lipid soluble moiety. For example, the peptides may be conjugated to myristic acid. The peptides may be myristoylated by standard techniques as described in Eichholtz et at., J. Biol. Chem. 268:1982-1986 (1993), incorporated herein by reference. Alternatively, the peptides may be packaged in liposomes that may fuse with cell membranes and deliver the peptides into the cells. Encapsulation of the peptides in liposomes may also be performed by standard techniques as generally described in U.S. Pat. Nos. 4,766,046; 5,169,637; 5,180,713; 5,185,154; 5,204,112; and 5,252,263 and PCT Patent Application No. 92/02244, each of which is incorporated herein by reference.

Another aspect of the invention provides polynucleotides encoding the protein binding fragments of gravin. Polynucleotides of the invention include DNA (i.e., genomic, complementary, and synthetic) and RNA. Sense and antisense polynucleotides, complementary to coding and noncoding polynucleotides are also contemplated. The polynucleotides of the present invention can be generated and purified by any number of standard, well-known techniques in the art. Also contemplated are polynucleotides which code for the polypeptides of the present invention based upon degeneracy of the genetic code. In addition, polynucleotides which encode gravin (e.g., degenerate oligoiners) useful in polymerase chain reaction (PCR) technologies are contemplated. Polynucleotides encoding analogs of gravin or structurally related DNAs which hybridize under stringent hybridization conditions to the polynucleotides of the invention are also contemplated. Those of ordinary skill in the art will understand hybridization conditions described as "stringent."

Exemplary stringent hybridization conditions are as follows: hybridization at about 65.degree. C. in 3.times.SSC, 20 mM NaPO.sub.4 pH 6.8 and washing at about 65.degree. C. in 0.2.times.SSC. It is understood by those of skill in the art that variation in these conditions occurs based on the length and GC nucleotide base content of the sequences to be hybridized. Formulas standard in the art are appropriate for determining exact hybridization conditions. See Sambrook et al., 9.47-9.51 in Molecular Cloning, Cold Spring Harbor Laboratory Press, Cold Spring Harbor, N.Y. (1989).

Polynucleotides of the invention are useful for recombinant production of the kinase binding domain polypeptides. Vectors comprising polynucleotides encoding a kinase binding domain as well as promotor, selectable marker and other well-known vector components (e.g. origin of replication, multiple cloning sites, etc.) are also contemplated by the invention.

The skilled artisan will understand the various components of vectors, methods for manipulating and the uses of vectors in transforming or transfecting of host cells (prokaryotic and eukaryotic) and expressing the kinase binding domains of the present invention. Host cells, especially unicellular host cells such as procaryotic and eukaryotic cells, are stably or transiently transformed or transfected with DNAs of the invention in a manner allowing expression of the kinase binding fragments of gravin. Host cells of the invention are conspicuously useful in methods for the large scale production of protein binding fragments of gravin wherein the cells are grown in a suitable culture medium and the desired fragments are isolated from the cells or from the medium in which the cells are grown. Use of mammalian host cells is expected to provide for such post-translational modifications (e.g., myristoylation, glycosylation, proteolytic processing, lipidation and tyrosine, serine or threonine phosphorylation) as may be needed to confer biological activity on recombinant expression products of the invention.

Another aspect of this invention provides antibody substances (e.g., polyclonal and monoclonal antibodies, antibody fragments, single chain antibodies, chinmeric antibodies, CDR-grafted antibodies, humanized antibodies and the like) specifically immunoreactive with the protein binding domains of gravin. Antibody substances can be prepared by standard techniques using isolated naturally-occurring or recombinant gravin. The antibody substances are useful in modulating (i.e., blocking, inhibiting, or stimulating) the binding between gravin and the kinase and in detecting gravin in patients suffering from MG. In addition, cell lines, (e.g., hybridomas), or cell lines transformed with recombinant expression constructs which produce antibody substances of the invention are contemplated.

In another aspect, methods of identifying a modulator compound that inhibits or increases binding between a gravin polypeptide and a gravin binding partner (e.g., type II regulatory subunit of PKA or PKC) are contemplated. In one method, gravin or a polypeptide fragment thereof such as set out in SEQ ID NOs: 1, 2 or 3 and a binding partner are incubated in the presence and absence of a putative modulator compound under conditions suitable for binding. The amount of binding in the presence and in the absence of the putative test compound is determined and compared. A reduction in the amount of binding observed in the presence of the test compound indicates that the test compound is an inhibitor. An increase in the amount of binding observed in the presence of the test compound indicates that the test compound increases binding between gravin and the binding partner. In one embodiment, either gravin or the binding partner can be immobilized on a solid substrate, and either gravin or the binding partner is detectably labeled. In addition, other assays, such as scintillation proximity assays may also be employed.

Modulators are useful for example, in inhibiting localization of a gravin binding partner (e.g. PKA, PKC, or other kinases) to a specific subcellular location. The contemplated modulators include polypeptides, polypeptide fragments of gravin and other organic and inorganic compounds.

The DNA sequence information provided by the present invention also makes possible the development, by homologous recombination or "knockout" strategies [see e.g. Capecchi, Science 244:1288-1292 (1989)] of mammals that fail to express functional gravin or that express an analog of gravin. The mammals of the present invention comprise a disruption of the gravin gene of the mammal or the disruption of a homolog of the gravin gene. The general strategy utilized to produce the mammals of the present invention involves the preparation of a targeting construct comprising DNA sequences homologous to the endogenous gene to be disrupted. The targeting construct is then introduced into embryonic stem cells (ES cells) whereby it integrates into and disrupts the endogenous gene or homolog thereof. After selecting cells which include the desired disruption, the selected ES cells are implanted into an embryo at the blastocyst stage. Exemplary mammals include rodent species.

Numerous additional aspects and advantages of the present invention will be apparent from the following detailed description of illustrative embodiments thereof.

BRIEF DESCRIPTION OF THE DRAWINGS

FIG. 1A. Binding properties of immobilized gravin fragment measured over a range of R11.alpha. 1-45 concentrations from 25-150 nM.

FIG. 1B. Uniform first order binding of immobilized gravin fragment.

FIG. 2. Effect of gravin fragment (SEQ ID NO:3) on PKC activity toward the peptide substrate VRKRTLRRL (SEQ ID NO:24).

DETAILED DESCRIPTION OF THE INVENTION

The present invention is illustrated by the following examples. Example 1 describes the cloning and characterization of a cDNA encoding gravin. The mapping and identification of a fragment of gravin that binds to the type II regulatory subunit of PKA is disclosed in Example 2. Example 3 describes the expression of full length gravin in COS cells. Example 4 describes the mapping and identification of a PKC binding fragment of gravin. Example 5 discusses the preparation of monoclonal and polyclonal antibodies. Experiments describing gravin expression in human erythroleukemia cells (HEL) is provided in Example 6. Example 7 describes experiments identifying tissue distribution of gravin. Example 8 describes the role of gravin in signal transduction and Example 9 describes binding assays utilizing gravin an a binding partner. Example 10 describes gravin's role in cell adhesion. In light of the present disclosure, those of skill in the art will appreciate that the following examples are intended to be illustrative only and that numerous changes, modifications and alterations can be made without departing from the spirit and scope of the invention.

EXAMPLE 1

To isolate cDNAs encoding potential RII binding proteins, a human fetal brain .lambda.-ZAP cDNA library was screened by a modified overlay procedure using radiolabeled RII.alpha. as a probe [Lohmann et al., Proc. Natl. Acad. Sci. U.S.A., 81:6723-6727 (1984)]. Eight RII binding clones were identified, plaque purified and the ends of each insert were sequenced. Two of the clones represented known sequences. One matched MAP2, a previously identified AKAP [Theurkauf et al., J. Biol. Chem., 257:3284-3290 (1982)]. The 3' end of another clone, designated HF 9, was identical to a previously described partial clone encoding gravin, which was originally isolated by screening a Human Umbilical Vein Endothelial cell (HUVE) cDNA library with serum from a Myasthenia gravis patient [Gordon et al., 1992].

Further sequencing of clone HF 9 showed that the cDNA insert was 3023 base pairs in length and encoded a continuous open reading frame of 651 amino acids. Northern blot analysis using a .sup.32 p random primed 1676 base pair Eco RI-Spe I fragment of HF 9 as a probe indicated that gravin mRNA was selectively expressed in certain human tissues. Two predominant mRNA species of 8.4 kb and 6.7 kb were detected in all tissues but predominated in liver, brain and lung, whereas an additional 5.5 kb message was detected in brain. The larger sizes of all the gravin messages, indicated that the HF 9 clone represented a partial cDNA. Therefore, the 1676 base pair HF 9 fragment was used to further screen the human fetal brain cDNA library for more complete transcripts. Five additional clones were obtained that yielded an additional 600 base pairs of coding region. As an alternative strategy, a human heart cDNA library was screened with the same 1676 base pair HF 9 fragment. Of the five positive clones isolated from the heart cDNA library, the longest clone contained a 4216 base pair insert, which overlapped with the 5' end of HF 9. This provided a contiguous composite sequence of 6605 base pairs encoding a protein of 1780 amino acids. The complete DNA and amino acid sequences of this protein, human gravin, are presented in SEQ ID NO: 4 and 5, respectively.

EXAMPLE 2

The last 651 amino acids of gravin were demonstrated to contain a binding site for association with the type II regulatory subunit of PKA. It was previously shown that regions of conserved secondary structure which are likely to include amphipathic u-helices are responsible for RII-binding [Carr et al., J. Biol. Chem., 267:13376-13382 (1992)]. Residues 1540-1553 LETKSSKLVQNIIQ (SEQ ID NO: 6) of gravin fulfilled these criteria. These residues also show sequence identity with corresponding regions in other AKAPs and a helical-wheel plot suggested that there was a segregation of hydrophobic and hydrophilic side-chains which is compatible with the formation of an amphipathic helix. The RII.alpha. binding fragment of gravin also shows some sequence homology to the corresponding RII binding regions in AKAP79 (LIETASSLVKNAIQ) (SEQ ID NO: 7) and in Ht31 (DLIEEAASRIVDAVIEQVKAAGA) (SEQ ID NO: 8). Ht31 is a sequence derived from human thyroid AKAP.

To identify the RII binding site(s) of gravin, a family of recombinant DNAs encoding fragments of gravin were generated by PCR using HF9 as the template. The polynucleotides encoding these fragments were subcloned into the pET16d plasmid which provides nucleotide sequences encoding a histine tag expressed at the amino terminus of the expressed gravin fragment. These constructs were expressed in E. coli and purified using the pET16d Histag bacterial expression/affinity purification system. Constructs encoding putative RII-binding site residues 1130-1582 (SEQ ID NO: 17) and 1130-1525 (SEQ ID NO: 15) of gravin were generated by utilizing a common 5' primer, CCGCCATGGTGCATATGTCCGAGTCCAGTGAGC, (SEQ ID NO: 9) but utilized distinct 3' primers: GCGCGGATCCGCACTCACTTTGACCTCCTG (SEQ ID NO: 10) for residues 1130-1525 (SEQ ID NO: 15) and GCGCGGATCCGCTATCACGTGAGCTTGTGT (SEQ ID NO: 11) for residues 1130-1582 (SEQ ID NO: 14). The 1526-1780 (SEQ ID NO: 16) construct was prepared by using the 5' primer, CCGCCATGGTGCATATGGTAGCAATTGAGGATTTAG (SEQ ID NO: 12) in conjunction with the 3' primer, GGAGGATCCAGAGATTCTGTAGTTCTG (SEQ ID NO: 13) used to subclone the full length clone. Each gravin construct was transfected into E. coli and the expression of recombinant Histag fusion proteins was induced by IPTG. Each recombinant protein was purified according to previously published methods [Coghlan et al., Science, 267:108-111 (1995b)].

The gravin fragments were screened for RII.alpha. binding using an overlay procedure essentially as described in Lohman et al., Proc. Nat. Acad. Sci., 81:6723-6727 (1984). Briefly, the overlay procedure is performed as follows. Protein samples are separated by SDS polyacrylamide gel electrophoresis (PAGE) and transferred to nitrocellulose by standard electrotransfer techniques. The immobilized protein is partially renatured by incubation in a blocking solution containing milk proteins then probed with .sup.32 p-labelled RII probe. After removal of unbound probe by washing, binding between gravin polypeptide fragments and RII is detected by autoradiography. To increase sensitivity of the assay (up to ten-fold), bound RII is detected immunologically (e.g. anti-RII-antisera and .sup.125 I-protein A, or monoclonal antibodies which specifically recognize RII.)

The 452 residue fragment encompassing residues 1130-1582 (SEQ ID NO: 14) bound .sup.32 P-radiolabeled RII.alpha. in the overlay, whereas a smaller fragment, residues 1130-1525 (SEQ ID NO: 15), which lacked the RII-binding region was unable to bind RII.alpha..

Two additional experiments provided evidence that the putative amphipathic helix region was sufficient for RII-binding. The fragment encompassing residues 1526-1780 (SEQ ID NO: 16) of gravin bound RII in the overlay and a synthetic peptide covering residues 1537-1563 (SEQ ID NO: 2) blocked all RII-binding in the overlay. In addition, the anchoring protein inhibitor peptide Ht31 (DLIEEAASRIVDAVIEQVKAAGA) (SEQ ID NO: 8) which is a competitive inhibitor of RII/AKAP interactions also blocked RII binding to gravin as assessed by the overlay assay. Control experiments in which overlays were performed in the presence of 0.3 .mu.M inhibitor polypeptide Ht31 (SEQ ID NO: 8) confirmed that the Ht31 inhibited binding between gravin and RII.alpha.. In addition a second control peptide, Ht31 -pro, (DLIEEAASRPVDAVIEQVKAAGA) (SEQ ID NO: 18) which is unable to block RII/AKAP binding was unable to inhibit binding between gravin and RII.alpha.. The second control peptide (SEQ ID NO: 18) is the Ht31 peptide in which an isoleucine has been replaced by a proline thereby disrupting the secondary structure. The Ht31 (SEQ ID NO: 8) peptide and Ht31-pro peptide were synthesized. To facilitate labeling and/or tracking of the control peptides, an additional tyrosine (radioiodination) or lysine (biotin/avidin) residue was sometimes included at the C-tenninus of the control peptides. This data demonstrates that gravin is an AKAP and its principle RII-binding site is encompassed by residues 1526-1582 (SEQ ID NO: 1).

This finding was further confinned when the binding affinity of the gravin 1526-1780 (SEQ ID NO: 16) fragment for a recombinant fragment of RII.alpha. was measured by surface plasmon resonance (SPR). SPR is an analytical technique that utilizes evanescent light to examine macromolecular complexes. The binding affinities of one protein to an immobilized binding partner can be measured by SPR. A recombinant fragment encompassing residues 1526-1780 (SEQ ID NO: 16) of gravin was coupled to a carboxymethyldextran IAsys cuvette using standard EDC/NHS coupling chemistry [Davies et al., Techniques in Protein Chemistry, 5:285-2992 (1994)]. The cuvette was activated by treating with 0.4 M EDC/0.1 M NHS for 8 min and washed extensively with PBST (PBS+0.05% Tween-20). Coupling of the gravin 1526-1780 fragment (SEQ ID NO: 16) (25 .mu.g/ml) was accomplished in 10 mM formate buffer, pH 3.6 for 10 min at room temperature. Uncoupled protein was washed out with PBST and free amines were blocked with 1M ethanolamine, pH 8.5 for 2 min at room temperature. After washing with PBST, a stable baseline was established for 10 min before data collection. All binding experiments were performed with a recombinant fragment of RII.alpha. (RII 1-45) [Scott, et al., Pro. Nat. Acad. Sci. 84:5192-5196 (1987)] which binds AKAPs with a similar affinity as the full-length protein. Previous experiments have indicated that release of RII.alpha. 1-45 from the binding surface can be performed under conditions that are less harmful to the immobilized anchoring protein than studies using full length RII. Binding experiments were performed over a range of concentrations from 25 to 150 nM in volumes of 200 .mu.l. The binding surface was regenerated between binding measurements using 60% ethanol with no decrease in extent measurements over the duration of an experiment. Data collection was done over three second intervals and was analyzed using the Fastfit.TM. software which was provided with the IAsys instrument. The binding properties of the immobilized gravin fragment were measured over a range of RII.alpha. 1-45 concentrations from 25 to 150 nM (FIG. 1A). Uniform first order binding was recorded with a K.sub.assc of 160006.+-.9700 M.sup.-1 sec.sup.-1 (n=3) and with a K.sub.dis, of 0.016.+-.0.001 M.sup.-1 (n=3) (FIG. 1B). These values were used to calculate a dissociation constant (KD) of 100 nM (n=3) for the RII/gravin fragment interaction (FIG. 1B). The nanomolar binding constant for RII/gravin interaction is well within the physiological concentration range of both proteins inside cells and is consistent with the notion that both proteins may associate in situ.

As demonstrated above, residues fragment 1537-1563 (SEQ ID NO: 2) of gravin form a PKA anchoring site. Of note, this sequence is present in the C-terminus of SSeCKS/clone 72 (see Example 4). Interestingly, this shared sequence has ten out of fourteen residues which are conserved in the RII-binding region of another mammalian scaffold protein, called AKAP79, which binds PKA, PKC and protein phosphatase 2B [Coghlan et al., 1995b; Klauck et al., 1996]. The identification of a conserved RII-binding sequence in gravin, SSeCKS/clone 72 and AKAP79 is the first example of conserved primary structure in known RII binding regions. This finding was unexpected as it was previously proposed that in spite of a lack of sequence identity among the AKAPs there existed a conservation of secondary structure in the RII-binding motif [Scott et al., 1994]. Therefore, it is likely that gravin, SSeCKS/clone 72 and AKAP 79 are members of a structurally related subfamily of AKAPs which bind more than one kinase or phosphatase.

EXAMPLE 3

In order to study the role of anchoring of PKA by gravin, full length gravin was expressed in cells that normally do not express the protein.

A plasmid containing the fill length gravin cDNA was prepared as follows. A 1.7 kb XbaI fragment was isolated from HF9 (containing the C-terminal sequece of Gravin) and cloned into pBSII (Strategene) containing the N-terminal 4216 bp clone (see Example 1) which was predigested with XbaI. Clones were screened and sequenced (on the 5' and 3' junctions) for correct orientation. The resulting clone is referred to as pBS/gravin. A EcoRI-Not1 fragment of pBS/Gravin was inserted in pcDNA3 predigested with EcoRI and Not1. Clones were screened for inserts by restriction digests using EcoRI and NotI. Correct clones were confirmed by sequencing the 5' and 3' junctions with primers DCO3 and JHSP6 respectively.

Transfection of Recombinant Gravin

COS cells were grown in 100 mm culture dishes until 20-40% confluent. Transfection of COS cells was performed as follows. The pcDNA3-gravin vector at a concentration of 10 .mu.g in 150 .mu.l serum free culture media was prepared to which was added 20 .mu.l of SuperFect (Qiagen, Chatsworth, Calif.). Media was removed from the COS cell culture and the cells washed with CMF-PBS. The SuperFect mixture was added to 3 ml of media with 10% FBS and added to the cells for three hours at 37.degree. C. Cells were then washed and fresh media added for an overnight incubation. Next, the cells were washed, trypsin harvested, washed again then lysed as described in Example 5. Transfection procedure for Jurkat cells was similar except the SuperFect mixture was added to Jurkat cells and left in the culture overnight. Cell lysates were prepared as described at 24, 48 hours and two weeks after transfection. Gravin expression was determined by Western blot analysis.

Transfected COS cells showed an enhanced gravin signal over baseline expression levels at twenty-four hours post transfection. Jurkat cells, which do not express gravin, showed significant expression of the recombinant protein from twenty-four hours post transfection out to two weeks. Recombinant gravin can thus be expressed and maintained in human cell lines.

EXAMPLE 4

Further sequence analysis revealed another potential function of gravin. A search of the nucleotide database using the complete gravin sequence showed that the first 1000 residues are 69% identical to a murine mitogenic regulatory protein SSeCKS [Lin et al., 1995)] also identified in the art as "clone 72", which was recently shown to be a protein kinase C binding-protein and also a protein kinase C substrate. [Chapline et al., 1996].

The ability of gravin to bind PKC was therefore examined. Accordingly, two recombinant gravin polypeptide fragments consisting of amino acids 265-556 (SEQ ID NO: 3) and 1130-1582 (SEQ ID NO: 14) were prepared and overlay analysis similar to the overlay analysis described in Example 2 was performed. The immobilized gravin fragments were incubated with PKC and the bound PKC was detected by using monoclonal antibodies to PKC (Transduction Labs, Lexington, Ky.) [Klauck, et al., (1996)]. The 265-556 (SEQ ID NO: 3) fragment was prepared by PCR using primers GACGAGATTGTGGAAATCCATGAGG (SEQ ID NO: 19) and GCGCGGATCCAGAGATFCTGTAGRFCTGAC (SEQ ID NO: 20). The 1130-1582 (SEQ ID NO: 14) fragment was prepared as described in Example 2. The results showed that PKC bound to the 265-556 fragment (SEQ ID NO: 3), but not to the 1130-1582 fragment (SEQ ID NO: 14). The overlay assay thus showed that the PKC binding fragment of gravin mapped to a region of the sequence between residues 265 to 556 (SEQ ID NO: 3). Neither of the gravin fragments bound PKC in the absence of phosphatidylserine (PS) which is consistent with other reports that phospholipid is a co-factor in the PKC/binding protein complex [Chapline et al., 1996]. It has been suggested that phosphatidylserine (PS) supports a ternary complex of PKC and polybasic regions on the substrate/binding protein [Liao et al., Biochem., 33:1229-1233 (1994)].

Polybasic regions were postulated to participate in formation of a phospholipid bridge between the PKC and its binding proteins [Chapline et al., 1996; Chapline et al., 1993]. In AKAP79, a polybasic region was identified as the PKC binding site [Klauck et al., 1996]. In gravin, there are two polybasic regions in the gravin 265-556 fragment (SEQ ID NO: 3) located between residues 295-316 (FKKFFTQGWAGWRKKTSFRKPK) (SEQ ID NO: 23) and 514-536 (PLKKLFTSTGLKKLSGKKQKGKR) (SEQ ID NO: 24). Both polybasic regions (residues 295-316 and residues 514-536) resemble the PKC-binding site on AKAP79. Synthetic peptides of both polybasic regions of gravin blocked PKC/gravin interactions when assessed by the overlay assay. These experiments show that protein kinase C binds gravin in vitro at one or more polybasic sites located between residues 265-556 of the protein.

The AKAP79 31-52 PKC binding site peptide KASMLCFKRRKKAAKLAKPKAG (SEQ ID NO: 23) blocked PKC binding to gravin. This result demonstrates that both gravin and AKAP79 likely bind to a similar site on PKC. Further similarity to AKAP79 was demonstrated when the gravin 265-556 (SEQ ID NO: 3) fragment was shown to inhibit PKC activity toward peptide substrate VRKRTLRRL (SEQ ID NO: 24) (Sigma Chemical Co., St. Louis, Mo.) with an IC.sub.50 of 0.50.+-.0.12 .mu.M (n=4) (FIG. 2). In contrast, the RII binding peptide did not inhibit the kinase. PKC activity was assayed as described [Orr et al., J. Biol. Chem., 269:27715-27718, 1994] in a reaction containing 40 mM HEPES (pH 7.5), 10 mM MgCl.sub.2, 0.3 mM CaCl.sub.2, 1 mM DTT, 100 .mu.M [.lambda..sup.32 P] adenosine triphosphate (ATP) (500 cpm/pmol), phosphatidylserine (20 .mu.g/ml), and epidermal growth factor receptor peptide (VRKRTLRRL) (SEQ ID NO: 24) as substrate at 30.degree. C. for 10 min. PKC .beta.II (20 ng/.mu.l) was diluted 1:10 in 20 mM Tris (pH 7.9), 1 mg/ml bovine serum albumin (BSA) and 1 mM DTT. Inhibition constants (IC.sub.50) were determined over an inhibition concentration range of 0.1 to 10 .mu.M gravin 265-556 fragment (SEQ ID NO: 3).

To date, three classes of PKC-binding proteins have been identified by gel overlay and two-hybrid techniques [Faux et al., Cell, 70:8-12 (1996a)]. PKC substrate/binding proteins [Chapline et al., 1993] and Receptors for Activated C-kinase (RACKs) [Mochly-Rosen et al., Proc. Natl. Acad. Sci. USA, 88:3997-4000, (1991)] have been detected by the gel-overlay procedure, while Proteins that Interact with C-kinase (PICKS), have been isolated in two-hybrid screens [Staudinger et al., 1995]. The data provided herein shows that a region of approximately 290 amino acids supports PKC-binding and fragments corresponding to that region block kinase activity in vitro.

EXAMPLE 5

Monoclonal antibodies are prepared by immunizing Balb/c mice subcutaneously with gravin or gravin fragments in complete Freund's adjuvant (CFA). Subsequent immunizations in CFA or incomplete Freund's adjuvant is performed to increase immune response.

The spleen of the immunized animal is removed aseptically and a single-cell suspension is formed by grinding the spleen between the frosted ends of two glass microscope slides submerged in serum free RPMI 1640, supplemented with 2 mM L-glutamine, 1 mM sodium pyruvate, 100 units/ml penicillin, and 100 .mu.g/ml streptomycin (RPMI) (Gibco, Canada). The cell suspension is filtered through sterile 70-mesh Nitex cell strainer (Becton Dickinson, Parsippany, N.J.), and washed twice by centrifuging at 200 g for 5 minutes and resuspending the pellet in 20 ml serum free RPMI. Thymocytes taken from naive Balb/c mice are prepared in the same manner.

2.times.10.sup.8 spleen cells are combined with 4.times.10.sup.7 NS-1 cells (kept in log phase in RPMI with 11% fetal bovine serum (FBS) for three days prior to fusion), centrifuged and the supernatant is aspirated. The cell pellet is dislodged and 2 ml of 37.degree. C. PEG 1500 (50% in 75 mM HEPES, pH 8.0) (Boehringer Mannheim) is added while stirring over the course of one minute, followed by the addition of 14 ml of serum free RPMI over seven minutes. Additional RPMI can be added and the cells are centrifuged at 200 g for 10 minutes. After discarding the supernatant, the pellet is resuspended in 200 ml RPMI containing 15% FBS, 100 mM sodium hypoxanthine, 0.4 mM aminopterin, 16 mM thymidine (HAT) (Gibco), 25 units/ml IL-6 (Boehringer Mannheim) and 1.5.times.10.sup.6 thymocytes/ml. The suspension is dispensed into ten 96-well flat bottom tissue culture plates (Corning, United Kingdom) at 200 .mu.l/well. Cells are fed on days 2, 4, and 6 days post-fusion by aspirating 100 .mu.l from each well with an 18 G needle (Becton Dickinson), and adding 100 .mu.l/well plating medium containing 10 U/ml IL-6 and lacking thymocytes.

When cell growth reaches 60-80% confluence (day 8-10), culture supernatants are taken from each well and screened for reactivity to gravin by ELISA. ELISAs are performed as follows. Immulon 4 plates (Dynatech, Cambridge, Mass.) were coated at 4.degree. C. with 50 .mu.l/well with 100 ng/well of p1110.delta.:GST or GST in 50 mM carbonate buffer, pH 9.6. Plates are washed with PBS with 0.05%, Tween 20 (PBST) and blocked 30 minutes at 37.degree. C. with 0.5% Fish Skin Gelatin. Plates are washed as described above and 50 .mu.l culture supernatant is added. After incubation at 37.degree. C. for 30 minutes, 50 .mu.l of horseradish peroxidase conjugated goat anti-mouse IgG(fc) (Jackson ImmunoResearch, West Grove, Pa.) [diluted 1:10,000 in PBST] is added. Plates are incubated at 37.degree. C. for 30 minutes, washed with PBST and 100 .mu.l of substrate, consisting of 1 mg/ml TMB (Sigma) and 0.15 ml/ml 30% H.sub.2 O.sub.2 in 100 mM Citrate, pH 4.5, is added. The color reaction is stopped with the addition of 50 ml of 15% H.sub.2 SO.sub.4. A.sub.450 is read on a plate reader (Dynatech).

Polyclonal antibodies are prepared by immunizing an animal with an antigen comprising a polypeptide of the present invention and collecting antisera from the immunized animal. A variety of animal species including rabbit, chicken, mouse, rat, or guinea pig are useful in preparation of polyclonal antibodies. The 1130-1780 (SEQ ID NO: 17) gravin fragment was used to prepare polyclonal antibodies in rabbit. Rabbit polyclonal antisera R3698 was produced from the 1130-1780 gravin fragment (SEQ ID NO: 17) by a commercial laboratory (Bethyl Labs, Montgomery, Tex.). The 1130-1780 fragment (SEQ ID NO: 17) was made by preparing and expressing a polynucleotide encoding the 1130-1780 fragment (SEQ ID NO: 9) (generated by PCR using the 5' primer, CCGCCATGGTGCATATGTCCGAGTCCAGTGAGC, (SEQ ID NO: 9) and the 3' primer, GGAGGATCCAGAGATTCTGTAGTTCTG (SEQ ID NO: 13)) as described in Example 2. In addition, the 265-556 fragment (SEQ ID NO: 3) was used to prepare polyclonal antibodies in rabbit and chicken. Rabbit polyclonal antisera, R4310 and chicken polyclonal antisera were produced from the 265-556 fragment (SEQ ID NO: 3) by Bethyl Labs.

Two additional polyclonal antisera were prepared. Two rabbits (4037J and 3548J) were immunized (R&R Rabbitry, Stanwood, Wash.) with 25-50 .mu.g of recombinant gravin fragment 265-556 for a total of three injections and a final boost. Test sera and pre-immune sera were tested by Western blot analysis. Recombinant protein (1 .mu.g/lane) and lysates from HEL cells (25 .mu.g/lane) grown with or without 40 .mu.g/ml PMA to induce gravin expression were separated by 4-12% SDS-PAGE (Novex, San Diego, Calif.) and transferred to immobilon by standard techniques. Resulting blots were incubated in blocking buffer (TBS with 5% milk proteins) to partially renature immobilized protein, then probed with rabbit sera (1:500 dilution in blocking buffer). Unbound antibodies were removed by washing in TBS, followed by incubation with a secondary goat anti-rabbit horse radish peroxidase (HRP) conjugated antibody (1:7500 dilution) in blocking buffer. Unbound antibody was washed away and the blots were developed by enhanced chemiluminescence (ECL, Dupont-NEN, Boston, Mass.) and exposed on film.

Sera from both rabbits recognized the recombinant gravin fragment. A 250 kDa band was detected in the PMA stimulated HEL cell lysate, but not in the lysate prepared from unstimulated REL cells. Serum from rabbit 4037J had the higher sensitivity by Western blot and so this antibody was purified by Protein A affinity chromatography.

EXAMPLE 6

Phorbol ester treatment of a human erythroleukemia cell line (HEL) (HEL 92.1.7, ATCC TIB 180) induces morphological, functional and biochemical changes that are characteristic of macrophage-like cells. One hallmark of this process is the robust induction of gravin [Gordon et al., 1992]. Therefore, the PKA and PKC binding protein profile of HEL cells after prolonged exposure to phorbol esters was examined.

HEL cells were grown in RPMI 1640 containing 12% fetal calf serum and 4 mM glutamine. Gravin expression was induced by culturing with 40 nM phorbol myristate acetate (PMA) for 18 hr. Cell lysates were prepared from either adherent cells grown in the presence of PMA, rinsed with PBS and scraped from the interior of 150 cm.sup.2 flasks or from suspension cultures of HEL cells grown in the absence of PMA. Cell pellets were washed twice with PBS prior to resuspension in 20 mM TrisHCl, pH 7.4, 150 mM NaCl, 10 mM EDTA, 0.25% Triton X-100, 0.05% Tween 20, 0.02% NaN.sub.3, 10 mM benzamidine, 2 .mu.g/ml pepstatin, 2 .mu.g/ml leupeptin, 4 mM 4-(2-aminoethyl)-benzenesulfonyl fluoride hydrochloride (Lysis Buffer) and incubation on ice for 10 min. The extracts were then centrifuged for 10 min at 16,000.times.g at 4.degree. C. and the cell lysate supernatant was collected. Protein concentrations were measured using the Bio-Rad DC Protein Assay kit.

The extracts from control and treated cells were subjected to western blot analysis with an affinity purified antibody raised against residues 130 to 1780 of gravin (See Example 5). PMA treatment caused an induction of a 250 kDa protein that specifically reacted with anti-gravin antibodies. Subsequent overlay assays demonstrated that PMA treatment induced the expression of a 250 kDa PKC-binding protein and an RII-binding protein of the same size.

Concomitant with the macrophage-like shift, HEL cells undergoing PMA treatment become adherent and display a considerable cytoplasmic spread [Papayannopoulou et al., Blood, 62:832-845 (1983)]. This sometimes results in the formation of actin stress fibers and causes a general flattening of the cell. In order to establish whether gravin aligned with the actin cytoskeleton, phorbol ester treated HEL cells were stained with rhodamine phalloidin as a marker for actin as described below.

HEL cells were grown on glass coverslips in the presence of 40 nM PMA for 18 hr, rinsed with PBS, fixed in 3.7% formaldehyde and extracted in -20.degree. C. absolute acetone. Cells were rehydrated for 1 hr in PBS and 0.2% BSA and then incubated with either affinity purified anti-gravin antibody, R3698, at 0.5 .mu.g/ml or pre-immune IgG at 0.5 .mu.g/ml. After 1 hr the coverslips were carefully washed in PBS and 0.2% BSA and incubated with either a mixture of FITC conjugated donkey anti-rabbit secondary antibody (1:100 dilution, Jackson ImmunoReasearch Laboratories Inc, West Grove, Pa.) and rhodamine conjugated phalloidin (1 unit/coverslip, Molecular Probes, Inc, Eugene, Oreg.) or secondary antibody alone. In situ RII-overlays were performed essentially as described [Coghlan et al., J. Biol. Chem., 269:7658-7665 (1994)]. Prior to incubation with primary antibody, cells were incubated with 80 nM recombinant murine RII for 2 hr and unbound RII removed by washing three times in PBS and 0.2% BSA. The immobilized RII.alpha. was detected immunochemically with affinity purified goat anti-murine RII (1 .mu.g/ml) and Texas red conjugated donkey anti-goat IgG secondary (1:100 dilution, Jackson ImmunoReasearch Laboratories Inc, West Grove, Pa.). Control coverslips were treated with the antibody to RII in the absence of exogenous murine RII. Cells were examined using a Leica confocal laser scanning system equipped with a Leitz Fluovert-FU inverted microscope and an argon/krypton laser.

All of the cells displayed a concentration of actin to the periphery. In contrast, gravin staining was predominantly cytoplasmic and only a subset of the cells (approximately 25%) expressed large quantities of the protein. Variable levels of gravin expression were not unexpected as HEL cells represent a heterogeneous population at different stages of differentiation [Papayannopoulou et al., 1983]. Superimposition of images of cells stained for actin and cells stained for gravin showed that both proteins exhibit distinct but partially overlapping subcellular distributions. Control experiments were negative when cells were stained with preimmune serum. More detailed confocal analysis of HEL cells detected gravin staining toward the periphery of the cell and enriched in filopodia at the adherent surface. These findings indicate that gravin functions to enhance HEL cell adhesion to the substratum.

Co-localization of Gravin and PKA

In vitro binding studies described in Examples 2 and 4 indicate that gravin is a kinase scaffold protein. Therefore, co-localization experiments were initiated to determine whether a gravin signaling complex could be detected in HEL cells. Fixed and permeabilized cells pre-treated with PMA were overlayed with recombinant murine RII.alpha.. RII-binding in situ was detected with antibodies that specifically recognize murine RII and mimicked the staining pattern for gravin. Since control experiments confirmed that the anti-murine RII antibodies did not detect the endogenous human RII, the increased RII staining was due to direct association with gravin. This conclusion was supported by additional control experiments showing that in situ RII-binding was blocked by incubation with the Ht 31 anchoring inhibitor peptide.

Finally, the gravin signaling complex was isolated by two complementary biochemical methods: immunoprecipitation and affinity chromatography on cAMP-agarose.

Immunoprecipitation of gravin was performed as follows. HEL cell lysates (200 .mu.l of 15 mg/ml) prepared as described above were incubated with either 15 .mu.g of affinity purified anti-gravin or 15 .mu.g of pre-immune IgG at 4.degree. C. for 18 hr. Immune complexes were isolated by the addition of 200 .mu.l of 10% (v/v) Protein A-Sepharose CL-4B (Sigma, St Louis, Mo.) which had been pre-equilibrated in Lysis Buffer. Following incubation at 4.degree. C. for 90 min the beads were washed once in 0.5 M NaCl Lysis Buffer and four times in excess 20 mM TrisHCl, pH 7.4, 150 mM NaCl. The PKA catalytic subunit was released from the immune complex by incubating the Protein-A beads in 200 .mu.l 1 mM cAMP, 20 mM TrisHCl, pH 7.4, 150 nM NaCl for 15 min. The eluate was TCA precipitated prior to analysis on a 4-15% SDS-PAGE gel, electroblotted onto nitrocellulose and the catalytic subunit was detected, as previously described. For the immunoprecipitation and detection of gravin, elution was accomplished by boiling the washed beads in SDS-PAGE sample buffer, separation of proteins on a 4-15% denaturing PAGE gel (5 .mu.g/lane), transfer to nitrocellulose and analysis by gravin western, PKC overlay and RII overlay western [as described above and previously [Klauck et al., 1996].

Gravin was affinity purified by incubating HEL cell lysates (400 .mu.l of 15 mg/ml, prepared as described above with the addition of 10 mM IBMX to the buffer), with 200 .mu.l packed cAMP-agarose (Sigma, St Louis, Mo.) which had been equilibrated in Lysis Buffer with 10 mM IBMX. The slurry was gently mixed for 18 hr at 4.degree. C. and then washed with 1.5 ml Lysis Buffer with 1 M NaCl followed by four 1.5 ml washes with 20 mM TrisHCl, pH 7.4, 150 mM NaCl. Elution was accomplished by incubating the beads in 0.5 ml 75 mM cAMP, 20 mM TrisHCl, pH 7.4, 150 mM NaCl for 30 min at room temperature. The final wash and the eluate were TCA precipitated and the entire sample loaded into a single lane on a 4-15% SDS-PAGE gel. The separated proteins were blotted to nitrocellulose and gravin was identified by western analysis as described above.

Immunoprecipitation with gravin antibodies specifically isolated a 250 kDa protein that could be faintly detected when SDS gels were stained with Coomassie Blue. This 250 kDa protein was present only in immunoprecipitates using the affinity purified gravin antibodies and was not detected in control experiments performed with pre-immune serum. Western blot and overlay assays confinred that the 250 kDa protein was gravin. Moreover, co-precipitation of the PKA holoenzyme was demonstrated by detection of the catalytic subunit in fractions eluted from the immunoprecipitate with cAMP but not in experimental fractions treated with pre-immune serum. The R subunit in the immunoprecipitates was undetectable because the 54 kDa protein migrates with the same mobility as the IgG heavy chain. However, the R subunit/gravin complex was purified from PMA induced HEL cell extracts by affinity chromatography on cAMP-agarose. After extensive washing in high salt buffers, gravin was eluted from the affinity resin with 75 mM cAMP. Since free gravin is refractive to the affinity resin, the protein detected in the eluate was associated with the regulatory subunit. Both co-purification techniques strongly suggest that the PKA holoenzyme is associated with gravin in vivo.

EXAMPLE 7

As previously discussed, thus far gravin has only been detected in human fibroblasts, neurons and endothelial cells. To determine if gravin has a more broad cell distribution or could be induced in other cell types, antibody 4037J was used against lysates of primary human cells and a variety of human, monkey, rat and murine cell lines to detect expression by Western blot analysis.

Preparation of Cells

Primary peripheral blood mononuclear cells (PBMC) were isolated from heparinzied peripheral blood from adult volunteers. Blood was diluted 1:1 with CMF-PBS and centrifuged over Histopaque (Sigma, St. Louis, Mo.) at a density of 1.096 g/cm.sup.-3 for thirty minutes at 400.times.g. The resulting interface was collected and washed in CMF-PBS. Monocytes were isolated from PBMC (prepared as above) by an one hour incubation in a 100 mmn polystyrene culture plate (Corning) in RPMI media supplemented with 10% fetal bovine serum. Non-adherent cells were washed away with CMF-PBS. Adherent cells (monocytes) were scraped from the plastic with a rubber spatula, then washed in PBS. Polymorphonuclear cells (PMN) were islated from peripheral blood using the red blood cell/granulocyte fraction of the histopaque procedure described above. The cell pellet was resuspended in an equal volume of CMF-PBS and 3% dextran (Pharmacia, Uppsala, Sweden) in 0.9% NaCl for thirty minutes to allow for sedimentation of the red blood cells. The PMN enriched supernatant was collected and washed three times in CMF-PBS. Between washes residual red blood cells were subjected to hypotonic lysis in 1 ml of water for thirty seconds. Remaining cells were returned to isotonic conditions with 50 ml of CMF-PBS.

The following human cell lines were obtained from ATCC (American Type Culture Collection, Rockville, Md.) and maintained in RPMI.+-.10% fetal bovine serum: HEL (human erythroleukemia), A549 (human lung epithelia), HEK 293 (human embryonic kidney), HL60 (human promyelocytic leukemia), KU812 (immature human basophilic leukocyte), Jurkat (human T cell lymphoma), THP1.1 (human moncyte), RBL2H3 (rat basophilic leukemia), COS (monkey fibroblast), RAW309 (murine monocyte), RAW264.7 (murine monocyte), 3T3L1 (murine embryonic fibroblast), L929 (murine fibroblast) and EL4IL-2 (murine thymoma).

The cell cultures were incubated overnight in the presence of 40 ng/ml PMA, 10 ng/ml lipopolysaccharide (LPS), 10.sup.-8 M f-met-leu-phe (fMLP) (all from Sigma, St. Louis, Mo.) or 10 ng/ml tumor necrosis factor alpha (TNF.alpha., Boehringer Mannheim, Indianapolis, Ind.) to determine if gravin expression could be stimulated. Lysates from cell pellets were prepared and protein concentrations determined as previously described in Example 6. Cell lysates were assayed for gravin by western blot as described usin, Protein-A purified anti-gravin antibody 4037J at 5 .mu.g/ml.

Expression of Gravin in Various Cell Lines

Western analysis showed that a 250 Kd band was detected in several human cell lines including KU812, REK293, A549, THP 1.1 and murine cell lines 3T3L1 and L929. For primary human cells, only adherent monocytes expressed the 250 kDa band. With the exception of PMA stimulation of HEL cells (see Example 6), this band was not induced in any other cells with either PMA, LPS, fMLP or TNF.alpha.. These bands were confirmed to be RII binding proteins by an overlay assay as described in Example 2. The cells that expressed gravin shared a common feature of adherence to plastic or growth in cell clusters.

Co-immunoprecipitation of Gravin and RII

HEK293 cells were harvested from culture and a lysate was prepared as described in Example 4. HEK293 lysate (100 .mu.g) was incubated with 10 .mu.g of either 4037J (anti-gravin polyclonal) or 241A (anti-human RII monoclonal) antibody for two hours on ice. An equal volume of prewashed Protein G-Sepharose beads (Pharmacia, Uppsala, Sweden) were added and samples incubated for one hour on a rotor at 4.degree. C. The beads were washed three times in lysis buffer, then once in PBS. SDS sample buffer was added to the beads which were then boiled for two minutes at 100.degree. C. The samples were spun down and the supernatant recovered. The samples were run on to a 4-12% SDS-PAGE gel in duplicate lanes along with antibody (2 .mu.g), and cell lysate (25 .mu.g) as controls. Proteins were transferred to immobilon by standard techniques. Western analysis was performed on the resulting blots by the methods described in 6. One blot was probed with 4037J antibody and detected with a goat anti-rabbit IgG-HRP and the other blot was incubated with 241A antibody and detected with goat anti-mouse IgG-HRP.

In the gravin Western a 250 kDa band was detected in lanes containing the cell lysate, 4037J co-immunoprecipiate. and the 241A co-imunoprecipitate samples. In the RII western a 54 kDa band was detected in the cell lysate. In the lanes containing the 4037J and 241A co-immunoprecipitates, a doublet was detected with one band at 54 kDa and another band running slightly higher. This upper band aligned with the IgG lane indicating the lower band to be RII. These results demonstrate that gravin and RII are associated in cells and can be co-immunoprecipitated from cell lysates using either an anti-gravin or an anti-RII antibody.

EXAMPLE 8

The nicotinic acetylcholine receptor is a neurotransmitter-gated ion channel comprising five transmembrane polypeptides. The five polypeptides appear to form a transmembrane aqueous pore through which cations can flow. In response to the binding of acetylcholine, the ion channel "opens" and permits the flow of Na.sup.+ into the cell (sodium current). The influx of sodium ions causes membrane depolarization which signals the muscle to contract. Individual receptors appear to rapidly open and close during the period of time that acetylcholine remains bound to the receptor. Within a few hundred milliseconds of acetylcholine binding, the channel closes and prevents further flow of sodium current and the acetylcholine signal is terminated.

The sensitivity of the nicotinic acetylcholine receptor to acetylcholine is attenuated by the phosphorylation of the transmembrane polypeptides (desensitization). Prolonged exposure of the receptor to acetylcholine leads to desensitization of the receptor. PKA appears be involved in desensitization of the nicotinic acetylcholine receptor by phosphorylating serine and tyrosine residues of the five transmembrane polypeptides. Myasthenia gravis is an autoiminune disease associated with the development of antibodies to the nicotinic acetylcholine receptors.

The present invention contemplates that gravin functions to localize PKA and PKC to a particular subcellular area of the cell. The role of gravin in coordination of PKA and PKC targeting to cytoskeletal components would be analogous to the role of AKAP79 role in clustering PKA, PKC, and protein phosphatase 2B at the postsynaptic density which is a specialized structure of the dendritic cytoskeleton [Coghlan et al., 1995b; Klauck et al., 1996; Rosenmund et al., Nature, 368:853-856 (1994)1.

Modulators which inhibit or abolish binding between gravin and PKA and/or PKC are useful in modulating the localization of PKA and/or PKC to particular subcellular regions. These modulators may include polypeptides which specifically bind to gravin or fragments of gravin which bind to PKA and/or PKC, and other non-peptide compounds (e.g. isolated or synthetic organic or inorganic molecules) which specifically interact with gravin or fragments of gravin.

EXAMPLE 9

An assay to determine the binding of gravin to binding partners was developed. The C-terminal clone, HF9, containing the RII binding region of gravin, was cloned into a Thioredoxin (Trx) bacterial expression vector as described below. The C-terminal clone, pBSII9 (described in Example 3), containing the RII binding region of gravin in was cloned into a Thioredoxin (Trx) bacterial expression vector. Briefly, to construct a thioredoxin expression vector, an XbaI/HindIII thioredoxin fragment was subclonsed into pUC 19 containing a lac Z gene and a tacZ promotoer. The resulting plasmid was designated TRX F/S pUC19. In order to insert the HF9 clone into TRX F/S pUC19, an NcoI site was created with an oligonucleotide: Met1153, 5.dbd. TACAACCATGGACAGGCTATCCCC. (The NCO cleavage site is underlined). The 3' oligonucleotide used was T7 (Strategene). Amplification of pBS/HF9 with the two oligonucleotides resulted in a 3 kb fragment which was digested with NcoI and XhoI (the latter provided the polylinker of pBS). Then NcoI/XhoI fragment was ligated in frame with the thioredoxin gene in TRX F/S pUC19 (predigested with NcoI/XhoI). The fusion protein was expressed in E. Coli, induced with 1 mM IPTG to O.D..sub.600 of 0.7 at 30.degree. C. Cells were harvested, lysed with French Press under standard conditions.],

The protein-protein binding assays were performed as follows. Briefly, anti-Trx mouse monoclonal antibodies were passively captured onto Immulon plates (Dynatech) in PBS. Anti-Trx monoclonal antibody was prepared using the methods described in Example 5. Nonspecific sites in the wells were blocked at room temperature for one hour with a buffer containing 2.5% milk in 50 mM sodium citrate and 145 mM sodium chloride. E coli lysate containing Trx/C-terminal gravin was added to wells in PBS/0.2% BSA for overnight at 4.degree. C. Free and non-specific proteins were removed with several washes with PBS. Biotinylated RII (chemically biotinylated using standard procedures) was then used as a ligand, and added in PBS/0.02% BSA. After three hours of incubation at room temperature, unbound proteins were removed with multiple washes of PBS/0.05% Tween 20. Streptavidin-Eu (Wallac) was diluted 1:1000 in assay buffer (Wallac) and added to detect biotinylated RII/gravin complexes. After additional washes in PBS/0 05% Tween to remove non-specifically bound proteins, Enhancement solution (Wallac) diluted 1:1 in water was added and release of europium was measured by increased fluorescence using a DELFIA.sup.R Research Fluormeter (Model 1232, Wallac).

This protein-protein binding assay indicated that over 50% of the binding to gravin was pecific. Biotinylated RII bound to gravin in a specific and saturable manner. The Kd for the interaction was found to be approximately 50 nM, similar to that reported in Nauert el al, 1996 using surface plasmon resonance.

EXAMPLE 10

The amino acid sequence of gravin exhibits some similarity to SSeCKS/clone 322/clone 72 [Chapline et al., 1996]. There is approximately 69% homology in the first 1,000 amino acids of gravin and SSeCKS. Gravin also exhibits some homology in selected regions to myristoylated alanine rich PKC substrate (MARCKS) [Aderein, Cell, 71:713-716 (1992)]. However, the remainder of each of the protein sequences are distinct. Also, gravin is a protein of 1780 amino acids which migrates with a mobility of 250 kDa on SDS gels, whereas SSeCKS/clone 72 is 1687 residues and migrates at 207 kDa [Lin et al., (1995), Chaplin, et al., (1995) and National Center for Biotechnology Information accession no. 2210332A]. In addition, the identification of five prospective nuclear localization signals has led to the idea that SSeCKS is a nuclear protein [Lin et al., 1995], whereas immunochemical data clearly shows that gravin is cytoplasmic and likely to be a cytoskeletal component. Clone 322 was described as being a tumor suppressor gene which is down regulated in oncogene transformed cells. Based upon a sequence similarities between gravin and clone 72 (and clone 322), gravin may also function as a tumor suppressor gene.

It is well known in the art that cancerous cells are non-adhesive cells. The non-adhesive nature of malignant cancer cells allows these cells to metastasize. The release or de-adhesion of a cancer cell from matrix proteins or other cells is prerequisite to migration or metastasis to new sites. Transformed or tumorigenic cells may be converted to a less tumorigenic state by increased expression of cytoplasmic proteins such as alpha actinin or talin that function in cytoskeletal reorganization, adhesion and migration [Gluck et al., Cell Science, 107:1773-1782 (1994)].

A tissue survey has shown that gravin exhibits a restricted cellular distribution and is predominantly expressed in fibroblasts, neurons and cells derived from the neural crest [Grove et al., 1994]. Since each of these cell types participates in adherent, migratory or path-seeking functions, it was postulated that gravin may regulate membrane/cytoskeleton events [Grove et al., 1994]. This view has been further substantiated by the immunolocalization experiments described in Example 6 which indicates that gravin may concentrate PKA in the ruffles and filopodia of adherent HEL cells. In addition, the data disclosed in Example 6 point toward a role for gravin in cell adhesion. Phorbol ester induced adhesion in HEL cells [Papayannopoulou et al., 1983] is concomitant with the increased gravin expression; whereas loss of an adherent phenotype upon transformation of REF 52 fibroblasts with an SV40 derivative is coincident with the down-regulation of clone 72 [Chapline et al., 1996]. Since phosphorylation events help to maintain the integrity of the membrane/cytoskeleton it is also tempting to speculate that PKA and PKC anchoring by gravin may play a role in adherent processes.

Given that gravin is expressed in adherent cells, but not in non-adherent cells, and given that clone 72 is down-regulated in oncogene transformed cells, gravin is implicated in cancer biology. Similar to its function in localizing kinases near the nicotinic acetylcholine receptor, gravin may also localize one or more kinases near a cell adhesion molecule wherein the response to cellular signals or other stimuli causes the phosphorylation of the cell adhesion molecule. It has been reported that substitution of threonine residues in the cytoplasmic domain of the LFA-1.beta. subunit abolishes LFA-1 mediated cell adhesion [Hibbs, et al., J.Exp. Med., 174:1227-1238 (1991)]. These threonine residues appear to be phosphorylated during cellular activation [Valmu et al., J. Immunol., 155:1175-1183 (1995)]. These residues are conserved in other integrin .beta. subunits. Thus, phosphorylation may regulate cell adhesion mediated by several distinct integrins.

Modulators which inhibit or abolish binding between gravin and its binding partner are useful in modulating localization of the binding partner by gravin. For example, modulators may interfere with the localization of a kinase near cell adhesion molecules. These modulators may include polypeptides which specifically bind to gravin or fragments of gravin which bind to a gravin binding partner, and other non-peptide compounds (e.g. isolated or synthetic organic or inorganic molecules) which specifically interact with gravin or fragments of gravin.

Numerous modifications and variations in the practice of this invention are expected to occur to those of skill in the art. Consequently, only such limitations as appear in the appended claims should be placed on the invention.

__________________________________________________________________________# SEQUENCE LISTING- (1) GENERAL INFORMATION:- (iii) NUMBER OF SEQUENCES: 24- (2) INFORMATION FOR SEQ ID NO:1:- (i) SEQUENCE CHARACTERISTICS:#acids (A) LENGTH: 57 amino (B) TYPE: amino acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear- (xi) SEQUENCE DESCRIPTION: SEQ ID NO:1:- Val Ala Ile Glu Asp Leu Glu Pro Glu Asn Gl - #y Ile Leu Glu Leu Glu# 15- Thr Lys Ser Ser Lys Leu Val Gln Asn Ile Il - #e Gln Thr Ala Val Asp# 30- Gln Phe Val Arg Thr Glu Glu Thr Ala Thr Gl - #u Met Leu Thr Ser Glu# 45- Leu Gln Thr Gln Ala His Val Ile Lys# 55- (2) INFORMATION FOR SEQ ID NO:2:- (i) SEQUENCE CHARACTERISTICS:#acids (A) LENGTH: 27 amino (B) TYPE: amino acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear- (xi) SEQUENCE DESCRIPTION: SEQ ID NO:2:- Ile Leu Glu Leu Glu Thr Lys Ser Ser Lys Le - #u Val Gln Asn Ile Ile# 15- Gln Thr Ala Val Asp Gln Phe Val Arg Thr Gl - #u# 25- (2) INFORMATION FOR SEQ ID NO:3:- (i) SEQUENCE CHARACTERISTICS:#acids (A) LENGTH: 292 amino (B) TYPE: amino acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear- (xi) SEQUENCE DESCRIPTION: SEQ ID NO:3:- Lys Glu Glu Gly Glu Glu Lys Gln Glu Lys Gl - #u Pro Ser Lys Ser Ala# 15- Glu Ser Pro Thr Ser Pro Val Thr Ser Glu Th - #r Gly Ser Thr Phe Lys# 30- Lys Phe Phe Thr Gln Gly Trp Ala Gly Trp Ar - #g Lys Lys Thr Ser Phe# 45- Arg Lys Pro Lys Glu Asp Glu Val Glu Ala Se - #r Glu Lys Lys Lys Glu# 60- Gln Glu Pro Glu Lys Val Asp Thr Glu Glu As - #p Gly Lys Ala Glu Val#80- Ala Ser Glu Lys Leu Thr Ala Ser Glu Gln Al - #a His Pro Gln Glu Pro# 95- Ala Glu Ser Ala His Glu Pro Arg Leu Ser Al - #a Glu Tyr Glu Lys Val# 110- Glu Leu Pro Ser Glu Glu Gln Val Ser Gly Se - #r Gln Gly Pro Ser Glu# 125- Glu Lys Pro Ala Pro Leu Ala Thr Glu Val Ph - #e Asp Glu Lys Ile Glu# 140- Val His Gln Glu Glu Val Val Ala Glu Val Hi - #s Val Ser Thr Val Glu145 1 - #50 1 - #55 1 -#60- Glu Arg Thr Glu Glu Gln Lys Thr Glu Val Gl - #u Glu Thr Ala Gly Ser# 175- Val Pro Ala Glu Glu Leu Val Gly Met Asp Al - #a Glu Pro Gln Glu Ala# 190- Glu Pro Ala Lys Glu Leu Val Lys Leu Lys Gl - #u Thr Cys Val Ser Gly# 205- Glu Asp Pro Thr Gln Gly Ala Asp Leu Ser Pr - #o Asp Glu Lys Val Leu# 220- Ser Lys Pro Pro Glu Gly Val Val Ser Glu Va - #l Glu Met Leu Ser Ser225 2 - #30 2 - #35 2 -#40- Gln Glu Arg Met Lys Val Gln Gly Ser Pro Le - #u Lys Lys Leu Phe Thr# 255- Ser Thr Gly Leu Lys Lys Leu Ser Gly Lys Ly - #s Gln Lys Gly Lys Arg# 270- Gly Gly Gly Asp Glu Glu Ser Gly Glu His Th - #r Gln Val Pro Ala Asp# 285- Ser Pro Asp Ser 290- (2) INFORMATION FOR SEQ ID NO:4:- (i) SEQUENCE CHARACTERISTICS:#pairs (A) LENGTH: 6605 base (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear- (ii) MOLECULE TYPE: cDNA- (ix) FEATURE: (A) NAME/KEY: CDS (B) LOCATION: 192..5531- (xi) SEQUENCE DESCRIPTION: SEQ ID NO:4:- CCTTCTTTTA AGGAGTTTGC CGCGAGCGCG TCTCCTTCAT TCGCAGGCTG GG - #CGCGTTCG 60- CAGTCGGCTG GCGGCGAAGG AAGGCGCTCT CGGGACCTCA CGGGCGCGCG TC - #TTTTGGCT 120- CTTGCCCCTG TCCCTGCGGC TTGGGGAAAG CGTAACCCGG CGGCTAGGCG CG - #GGAGAAGT 180#CAG CGC AGC CCG GAG 230GG AGC TCC ACC GAG#Gly Ser Ser Thr Glu Gln Arg Ser Pro Glu# 10- CAG CCG CCC GAG GGG AGC TCC ACG CCG GCT GA - #G CCC GAG CCC AGC GGC 278Gln Pro Pro Glu Gly Ser Ser Thr Pro Ala Gl - #u Pro Glu Pro Ser Gly# 25- GGC GGC CCC TCG GCC GAG GCG GCG CCA GAC AC - #C ACC GCG GAC CCC GCC 326Gly Gly Pro Ser Ala Glu Ala Ala Pro Asp Th - #r Thr Ala Asp Pro Ala# 45- ATC GCT GCC TCG GAC CCC GCC ACC AAG CTC CT - #A CAG AAG AAT GGT CAG 374Ile Ala Ala Ser Asp Pro Ala Thr Lys Leu Le - #u Gln Lys Asn Gly Gln# 60- CTG TCC ACC ATC AAT GGC GTA GCT GAG CAA GA - #T GAG CTC AGC CTC CAG 422Leu Ser Thr Ile Asn Gly Val Ala Glu Gln As - #p Glu Leu Ser Leu Gln# 75- GAG GGT GAC CTA AAT GGC CAG AAA GGA GCC CT - #G AAC GGT CAA GGA GCC 470Glu Gly Asp Leu Asn Gly Gln Lys Gly Ala Le - #u Asn Gly Gln Gly Ala# 90- CTA AAC AGC CAG GAG GAA GAA GAA GTC ATT GT - #C ACG GAG GTT GGA CAG 518Leu Asn Ser Gln Glu Glu Glu Glu Val Ile Va - #l Thr Glu Val Gly Gln# 105- AGA GAC TCT GAA GAT GTG AGC GAA AGA GAC TC - #C GAT AAA GAG ATG GCT 566Arg Asp Ser Glu Asp Val Ser Glu Arg Asp Se - #r Asp Lys Glu Met Ala110 1 - #15 1 - #20 1 -#25- ACT AAG TCA GCG GTT GTT CAC GAC ATC ACA GA - #T GAT GGG CAG GAG GAG 614Thr Lys Ser Ala Val Val His Asp Ile Thr As - #p Asp Gly Gln Glu Glu# 140- AAC CGA AAT ATC GAA CAG ATT CCT TCT TCA GA - #A AGC AAT TTA GAA GAG 662Asn Arg Asn Ile Glu Gln Ile Pro Ser Ser Gl - #u Ser Asn Leu Glu Glu# 155- CTA ACA CAA CCC ACT GAG TCC CAG GCT AAT GA - #T ATT GGA TTT AAG AAG 710Leu Thr Gln Pro Thr Glu Ser Gln Ala Asn As - #p Ile Gly Phe Lys Lys# 170- GTG TTT AAG TTT GTT GGC TTT AAA TTC ACT GT - #G AAA AAG GAT AAG ACA 758Val Phe Lys Phe Val Gly Phe Lys Phe Thr Va - #l Lys Lys Asp Lys Thr# 185- GAG AAG CCT GAC ACT GTC CAG CTA CTC ACT GT - #G AAG AAA GAT GAA GGG 806Glu Lys Pro Asp Thr Val Gln Leu Leu Thr Va - #l Lys Lys Asp Glu Gly190 1 - #95 2 - #00 2 -#05- GAG GGA GCA GCA GGG GCT GGC GAC CAC CAG GA - #C CCC AGC CTT GGG GCT 854Glu Gly Ala Ala Gly Ala Gly Asp His Gln As - #p Pro Ser Leu Gly Ala# 220- GGA GAA GCA GCA TCC AAA GAA AGC GAA CCC AA - #A CAA TCT ACA GAG AAA 902Gly Glu Ala Ala Ser Lys Glu Ser Glu Pro Ly - #s Gln Ser Thr Glu Lys# 235- CCC GAA GAG ACC CTG AAG CGT GAG CAA AGC CA - #C GCA GAA ATT TCT CCC 950Pro Glu Glu Thr Leu Lys Arg Glu Gln Ser Hi - #s Ala Glu Ile Ser Pro# 250- CCA GCC GAA TCT GGC CAA GCA GTG GAG GAA TG - #C AAA GAG GAA GGA GAA 998Pro Ala Glu Ser Gly Gln Ala Val Glu Glu Cy - #s Lys Glu Glu Gly Glu# 265- GAG AAA CAA GAA AAA GAA CCT AGC AAG TCT GC - #A GAA TCT CCG ACT AGT1046Glu Lys Gln Glu Lys Glu Pro Ser Lys Ser Al - #a Glu Ser Pro Thr Ser270 2 - #75 2 - #80 2 -#85- CCC GTG ACC AGT GAA ACA GGA TCA ACC TTC AA - #A AAA TTC TTC ACT CAA1094Pro Val Thr Ser Glu Thr Gly Ser Thr Phe Ly - #s Lys Phe Phe Thr Gln# 300- GGT TGG GCC GGC TGG CGC AAA AAG ACC AGT TT - #C AGG AAG CCG AAG GAG1142Gly Trp Ala Gly Trp Arg Lys Lys Thr Ser Ph - #e Arg Lys Pro Lys Glu# 315- GAT GAA GTG GAA GCT TCA GAG AAG AAA AAG GA - #A CAA GAG CCA GAA AAA1190Asp Glu Val Glu Ala Ser Glu Lys Lys Lys Gl - #u Gln Glu Pro Glu Lys# 330- GTA GAC ACA GAA GAA GAC GGA AAG GCA GAG GT - #T GCC TCC GAG AAA CTG1238Val Asp Thr Glu Glu Asp Gly Lys Ala Glu Va - #l Ala Ser Glu Lys Leu# 345- ACC GCC TCC GAG CAA GCC CAC CCA CAG GAG CC - #G GCA GAA AGT GCC CAC1286Thr Ala Ser Glu Gln Ala His Pro Gln Glu Pr - #o Ala Glu Ser Ala His350 3 - #55 3 - #60 3 -#65- GAG CCC CGG TTA TCA GCT GAA TAT GAG AAA GT - #T GAG CTG CCC TCA GAG1334Glu Pro Arg Leu Ser Ala Glu Tyr Glu Lys Va - #l Glu Leu Pro Ser Glu# 380- GAG CAA GTC AGT GGC TCG CAG GGA CCT TCT GA - #A GAG AAA CCT GCT CCG1382Glu Gln Val Ser Gly Ser Gln Gly Pro Ser Gl - #u Glu Lys Pro Ala Pro# 395- TTG GCG ACA GAA GTG TTT GAT GAG AAA ATA GA - #A GTC CAC CAA GAA GAG1430Leu Ala Thr Glu Val Phe Asp Glu Lys Ile Gl - #u Val His Gln Glu Glu# 410- GTT GTG GCC GAA GTC CAC GTC AGC ACC GTG GA - #G GAG AGA ACC GAA GAG1478Val Val Ala Glu Val His Val Ser Thr Val Gl - #u Glu Arg Thr Glu Glu# 425- CAG AAA ACG GAG GTG GAA GAA ACA GCA GGG TC - #T GTG CCA GCT GAA GAA1526Gln Lys Thr Glu Val Glu Glu Thr Ala Gly Se - #r Val Pro Ala Glu Glu430 4 - #35 4 - #40 4 -#45- TTG GTT GGA ATG GAT GCA GAA CCT CAG GAA GC - #C GAA CCT GCC AAG GAG1574Leu Val Gly Met Asp Ala Glu Pro Gln Glu Al - #a Glu Pro Ala Lys Glu# 460- CTG GTG AAG CTC AAA GAA ACG TGT GTT TCC GG - #A GAG GAC CCT ACA CAG1622Leu Val Lys Leu Lys Glu Thr Cys Val Ser Gl - #y Glu Asp Pro Thr Gln# 475- GGA GCT GAC CTC AGT CCT GAT GAG AAG GTG CT - #G TCC AAA CCC CCC GAA1670Gly Ala Asp Leu Ser Pro Asp Glu Lys Val Le - #u Ser Lys Pro Pro Glu# 490- GGC GTT GTG AGT GAG GTG GAA ATG CTG TCA TC - #A CAG GAG AGA ATG AAG1718Gly Val Val Ser Glu Val Glu Met Leu Ser Se - #r Gln Glu Arg Met Lys# 505- GTG CAG GGA AGT CCA CTA AAG AAG CTT TTT AC - #C AGC ACT GGC TTA AAA1766Val Gln Gly Ser Pro Leu Lys Lys Leu Phe Th - #r Ser Thr Gly Leu Lys510 5 - #15 5 - #20 5 -#25- AAG CTT TCT GGA AAG AAA CAG AAA GGG AAA AG - #A GGA GGA GGA GAC GAG1814Lys Leu Ser Gly Lys Lys Gln Lys Gly Lys Ar - #g Gly Gly Gly Asp Glu# 540- GAA TCA GGG GAG CAC ACT CAG GTT CCA GCC GA - #T TCT CCG GAC AGC CAG1862Glu Ser Gly Glu His Thr Gln Val Pro Ala As - #p Ser Pro Asp Ser Gln# 555- GAG GAG CAA AAG GGC GAG AGC TCT GCC TCA TC - #C CCT GAG GAG CCC GAG1910Glu Glu Gln Lys Gly Glu Ser Ser Ala Ser Se - #r Pro Glu Glu Pro Glu# 570- GAG ATC ACG TGT CTG GAA AAG GGC TTA GCC GA - #G GTG CAG CAG GAT GGG1958Glu Ile Thr Cys Leu Glu Lys Gly Leu Ala Gl - #u Val Gln Gln Asp Gly# 585- GAA GCT GAA GAA GGA GCT ACT TCC GAT GGA GA - #G AAA AAA AGA GAA GGT2006Glu Ala Glu Glu Gly Ala Thr Ser Asp Gly Gl - #u Lys Lys Arg Glu Gly590 5 - #95 6 - #00 6 -#05- GTC ACT CCC TGG GCA TCA TTC AAA AAG ATG GT - #G ACG CCC AAG AAG CGT2054Val Thr Pro Trp Ala Ser Phe Lys Lys Met Va - #l Thr Pro Lys Lys Arg# 620- GTT AGA CGG CCT TCG GAA AGT GAT AAA GAA GA - #T GAG CTG GAC AAG GTC2102Val Arg Arg Pro Ser Glu Ser Asp Lys Glu As - #p Glu Leu Asp Lys Val# 635- AAG AGC GCT ACC TTG TCT TCC ACC GAG AGC AC - #A GCC TCT GAA ATG CAA2150Lys Ser Ala Thr Leu Ser Ser Thr Glu Ser Th - #r Ala Ser Glu Met Gln# 650- GAA GAA ATG AAA GGG AGC GTG GAA GAG CCA AA - #G CCG GAA GAA CCA AAG2198Glu Glu Met Lys Gly Ser Val Glu Glu Pro Ly - #s Pro Glu Glu Pro Lys# 665- CGC AAG GTG GAT ACC TCA GTA TCT TGG GAA GC - #T TTA ATT TGT GTG GGA2246Arg Lys Val Asp Thr Ser Val Ser Trp Glu Al - #a Leu Ile Cys Val Gly670 6 - #75 6 - #80 6 -#85- TCA TCC AAG AAA AGA GCA AGG AGA AGG TCC TC - #T TCT GAT GAG GAA GGG2294Ser Ser Lys Lys Arg Ala Arg Arg Arg Ser Se - #r Ser Asp Glu Glu Gly# 700- GGA CCA AAA GCA ATG GGA GGA GAC CAC CAG AA - #A GCT GAT GAG GCC GGA2342Gly Pro Lys Ala Met Gly Gly Asp His Gln Ly - #s Ala Asp Glu Ala Gly# 715- AAA GAC AAA GAG ACG GGG ACA GAC GGG ATC CT - #T GCT GGT TCC CAA GAA2390Lys Asp Lys Glu Thr Gly Thr Asp Gly Ile Le - #u Ala Gly Ser Gln Glu# 730- CAT GAT CCA GGG CAG GGA AGT TCC TCC CCG GA - #G CAA GCT GGA AGC CCT2438His Asp Pro Gly Gln Gly Ser Ser Ser Pro Gl - #u Gln Ala Gly Ser Pro# 745- ACC GAA GGG GAG GGC GTT TCC ACC TGG GAG TC - #A TTT AAA AGG TTA GTC2486Thr Glu Gly Glu Gly Val Ser Thr Trp Glu Se - #r Phe Lys Arg Leu Val750 7 - #55 7 - #60 7 -#65- ACG CCA AGA AAA AAA TCA AAG TCC AAG CTG GA - #A GAG AAA AGC GAA GAC2534Thr Pro Arg Lys Lys Ser Lys Ser Lys Leu Gl - #u Glu Lys Ser Glu Asp# 780- TCC ATA GCT GGG TCT GGT GTA GAA CAT TCC AC - #T CCA GAC ACT GAA CCC2582Ser Ile Ala Gly Ser Gly Val Glu His Ser Th - #r Pro Asp Thr Glu Pro# 795- GGT AAA GAA GAA TCC TGG GTC TCA ATC AAG AA - #G TTT ATT CCT GGA CGA2630Gly Lys Glu Glu Ser Trp Val Ser Ile Lys Ly - #s Phe Ile Pro Gly Arg# 810- AGG AAG AAA AGG CCA GAT GGG AAA CAA GAA CA - #A GCC CCT GTT GAA GAC2678Arg Lys Lys Arg Pro Asp Gly Lys Gln Glu Gl - #n Ala Pro Val Glu Asp# 825- GCA GGG CCA ACA GGG GCC AAC GAA GAT GAC TC - #T GAT GTC CCG GCC GTG2726Ala Gly Pro Thr Gly Ala Asn Glu Asp Asp Se - #r Asp Val Pro Ala Val830 8 - #35 8 - #40 8 -#45- GTC CCT CTG TCT GAG TAT GAT GCT GTA GAA AG - #G GAG AAA ATG GAG GCA2774Val Pro Leu Ser Glu Tyr Asp Ala Val Glu Ar - #g Glu Lys Met Glu Ala# 860- CAG CAA GCC CAA AAA GGC GCA GAG CAG CCC GA - #G CAG AAG GCA GCC ACT2822Gln Gln Ala Gln Lys Gly Ala Glu Gln Pro Gl - #u Gln Lys Ala Ala Thr# 875- GAG GTG TCC AAG GAG CTC AGC GAG AGT CAG GT - #T CAT ATG ATG GCA GCA2870Glu Val Ser Lys Glu Leu Ser Glu Ser Gln Va - #l His Met Met Ala Ala# 890- GCT GTC GCT GAC GGG ACG AGG GCA GCT ACC AT - #T ATT GAA GAA AGG TCT2918Ala Val Ala Asp Gly Thr Arg Ala Ala Thr Il - #e Ile Glu Glu Arg Ser# 905- CCT TCT TGG ATA TCT GCT TCA GTG ACA GAA CC - #T CTT GAA CAA GTA GAA2966Pro Ser Trp Ile Ser Ala Ser Val Thr Glu Pr - #o Leu Glu Gln Val Glu910 9 - #15 9 - #20 9 -#25- GCT GAA GCC GCA CTG TTA ACT GAG GAG GTA TT - #G GAA AGA GAA GTA ATT3014Ala Glu Ala Ala Leu Leu Thr Glu Glu Val Le - #u Glu Arg Glu Val Ile# 940- GCA GAA GAA GAA CCC CCC ACG GTT ACT GAA CC - #T CTG CCA GAG AAC AGA3062Ala Glu Glu Glu Pro Pro Thr Val Thr Glu Pr - #o Leu Pro Glu Asn Arg# 955- GAG GCC CGG GGC GAC ACG GTC GTT AGT GAG GC - #G GAA TTG ACC CCC GAA3110Glu Ala Arg Gly Asp Thr Val Val Ser Glu Al - #a Glu Leu Thr Pro Glu# 970- GCT GTG ACA GCT GCA GAA ACT GCA GGG CCA TT - #G GGT TCC GAA GAA GGA3158Ala Val Thr Ala Ala Glu Thr Ala Gly Pro Le - #u Gly Ser Glu Glu Gly# 985- ACC GAA GCA TCT GCT GCT GAA GAG ACC ACA GA - #A ATG GTG TCA GCA GTC3206Thr Glu Ala Ser Ala Ala Glu Glu Thr Thr Gl - #u Met Val Ser Ala Val990 9 - #95 1 - #000 1005- TCC CAG TTA ACC GAC TCC CCA GAC ACC ACA GA - #G GAG GCC ACT CCG GTG3254Ser Gln Leu Thr Asp Ser Pro Asp Thr Thr Gl - #u Glu Ala Thr Pro Val# 10205- CAG GAG GTG GAA GGT GGC GTA CCT GAC ATA GA - #A GAG CAA GAG AGG CGG3302Gln Glu Val Glu Gly Gly Val Pro Asp Ile Gl - #u Glu Gln Glu Arg Arg# 10350- ACT CAA GAG GTC CTC CAG GCA GTG GCA GAA AA - #A GTG AAA GAG GAA TCC3350Thr Gln Glu Val Leu Gln Ala Val Ala Glu Ly - #s Val Lys Glu Glu Ser# 10505- CAG CTG CCT GGC ACC GGT GGG CCA GAA GAT GT - #G CTT CAG CCT GTG CAG3398Gln Leu Pro Gly Thr Gly Gly Pro Glu Asp Va - #l Leu Gln Pro Val Gln# 10650- AGA GCA GAG GCA GAA AGA CCA GAA GAG CAG GC - #T GAA GCG TCG GGT CTG3446Arg Ala Glu Ala Glu Arg Pro Glu Glu Gln Al - #a Glu Ala Ser Gly Leu# 10851075 - # 1080- AAG AAA GAG ACG GAT GTA GTG TTG AAA GTA GA - #T GCT CAG GAG GCA AAA3494Lys Lys Glu Thr Asp Val Val Leu Lys Val As - #p Ala Gln Glu Ala Lys# 11005- ACT GAG CCT TTT ACA CAA GGG AAG GTG GTG GG - #G CAG ACC ACC CCA GAA3542Thr Glu Pro Phe Thr Gln Gly Lys Val Val Gl - #y Gln Thr Thr Pro Glu# 11150- AGC TTT GAA AAA GCT CCT CAA GTC ACA GAG AG - #C ATA GAG TCC AGT GAG3590Ser Phe Glu Lys Ala Pro Gln Val Thr Glu Se - #r Ile Glu Ser Ser Glu# 11305- CTT GTA ACC ACT TGT CAA GCC GAA ACC TTA GC - #T GGG GTA AAA TCA CAG3638Leu Val Thr Thr Cys Gln Ala Glu Thr Leu Al - #a Gly Val Lys Ser Gln# 11450- GAG ATG GTG ATG GAA CAG GCT ATC CCC CCT GA - #C TCG GTG GAA ACC CCT3686Glu Met Val Met Glu Gln Ala Ile Pro Pro As - #p Ser Val Glu Thr Pro# 11651155 - # 1160- ACA GAC AGT GAG ACT GAT GGA AGC ACC CCC GT - #A GCC GAC TTT GAC GCA3734Thr Asp Ser Glu Thr Asp Gly Ser Thr Pro Va - #l Ala Asp Phe Asp Ala# 11805- CCA GGC ACA ACC CAG AAA GAC GAG ATT GTG GA - #A ATC CAT GAG GAG AAT3782Pro Gly Thr Thr Gln Lys Asp Glu Ile Val Gl - #u Ile His Glu Glu Asn# 11950- GAG GTG CAT CTG GTA CCA GTC AGG GGC ACA GA - #A GCA GAG GCA GTT CCT3830Glu Val His Leu Val Pro Val Arg Gly Thr Gl - #u Ala Glu Ala Val Pro# 12105- GCA CAG AAA GAG AGG CCT CCA GCA CCT TCC AG - #T TTT GTG TTC CAG GAA3878Ala Gln Lys Glu Arg Pro Pro Ala Pro Ser Se - #r Phe Val Phe Gln Glu# 12250- GAA ACT AAA GAA CAA TCA AAG ATG GAA GAC AC - #T CTA GAG CAT ACA GAT3926Glu Thr Lys Glu Gln Ser Lys Met Glu Asp Th - #r Leu Glu His Thr Asp# 12451235 - # 1240- AAA GAG GTG TCA GTG GAA ACT GTA TCC ATT CT - #G TCA AAG ACT GAG GGG3974Lys Glu Val Ser Val Glu Thr Val Ser Ile Le - #u Ser Lys Thr Glu Gly# 12605- ACT CAA GAG GCT GAC CAG TAT GCT GAT GAG AA - #A ACC AAA GAC GTA CCA4022Thr Gln Glu Ala Asp Gln Tyr Ala Asp Glu Ly - #s Thr Lys Asp Val Pro# 12750- TTT TTC GAA GGA CTT GAG GGG TCT ATA GAC AC - #A GGC ATA ACA GTC AGT4070Phe Phe Glu Gly Leu Glu Gly Ser Ile Asp Th - #r Gly Ile Thr Val Ser# 12905- CGG GAA AAG GTC ACT GAA GTT GCC CTT AAA GG - #T GAA GGG ACA GAA GAA4118Arg Glu Lys Val Thr Glu Val Ala Leu Lys Gl - #y Glu Gly Thr Glu Glu# 13050- GCT GAA TGT AAA AAG GAT GAT GCT CTT GAA CT - #G CAG AGT CAC GCT AAG4166Ala Glu Cys Lys Lys Asp Asp Ala Leu Glu Le - #u Gln Ser His Ala Lys# 13251315 - # 1320- TCT CCT CCA TCC CCC GTG GAG AGA GAG ATG GT - #A GTT CAA GTC GAA AGG4214Ser Pro Pro Ser Pro Val Glu Arg Glu Met Va - #l Val Gln Val Glu Arg# 13405- GAG AAA ACA GAA GCA GAG CCA ACC CAT GTG AA - #T GAA GAG AAG CTT GAG4262Glu Lys Thr Glu Ala Glu Pro Thr His Val As - #n Glu Glu Lys Leu Glu# 13550- CAC GAA ACA GCT GTT ACC GTA TCT GAA GAG GT - #C AGT AAG CAG CTC CTC4310His Glu Thr Ala Val Thr Val Ser Glu Glu Va - #l Ser Lys Gln Leu Leu# 13705- CAG ACA GTG AAT GTG CCC ATC ATA GAT GGG GC - #A AAG GAA GTC AGC AGT4358Gln Thr Val Asn Val Pro Ile Ile Asp Gly Al - #a Lys Glu Val Ser Ser# 13850- TTG GAA GGA AGC CCT CCT CCC TGC CTA GGT CA - #A GAG GAG GCA GTA TGC4406Leu Glu Gly Ser Pro Pro Pro Cys Leu Gly Gl - #n Glu Glu Ala Val Cys# 14051395 - # 1400- ACC AAA ATT CAA GTT CAG AGC TCT GAG GCA TC - #A TTC ACT CTA ACA GCG4454Thr Lys Ile Gln Val Gln Ser Ser Glu Ala Se - #r Phe Thr Leu Thr Ala# 14205- GCT GCA GAG GAG GAA AAG GTC TTA GGA GAA AC - #T GCC AAC ATT TTA GAA4502Ala Ala Glu Glu Glu Lys Val Leu Gly Glu Th - #r Ala Asn Ile Leu Glu# 14350- ACA GGT GAA ACG TTG GAG CCT GCA GGT GCA CA - #T TTA GTT CTG GAA GAG4550Thr Gly Glu Thr Leu Glu Pro Ala Gly Ala Hi - #s Leu Val Leu Glu Glu# 14505- AAA TCC TCT GAA AAA AAT GAA GAC TTT GCC GC - #T CAT CCA GGG GAA GAT4598Lys Ser Ser Glu Lys Asn Glu Asp Phe Ala Al - #a His Pro Gly Glu Asp# 14650- GCT GTG CCC ACA GGG CCC GAC TGT CAG GCA AA - #A TCG ACA CCA GTG ATA4646Ala Val Pro Thr Gly Pro Asp Cys Gln Ala Ly - #s Ser Thr Pro Val Ile# 14851475 - # 1480- GTA TCT GCT ACT ACC AAG AAA GGC TTA AGT TC - #C GAC CTG GAA GGA GAG4694Val Ser Ala Thr Thr Lys Lys Gly Leu Ser Se - #r Asp Leu Glu Gly Glu# 15005- AAA ACC ACA TCA CTG AAG TGG AAG TCA GAT GA - #A GTC GAT GAG CAG GTT4742Lys Thr Thr Ser Leu Lys Trp Lys Ser Asp Gl - #u Val Asp Glu Gln Val# 15150- GCT TGC CAG GAG GTC AAA GTG AGT GTA GCA AT - #T GAG GAT TTA GAG CCT4790Ala Cys Gln Glu Val Lys Val Ser Val Ala Il - #e Glu Asp Leu Glu Pro# 15305- GAA AAT GGG ATT TTG GAA CTT GAG ACC AAA AG - #C AGT AAA CTT GTC CAA4838Glu Asn Gly Ile Leu Glu Leu Glu Thr Lys Se - #r Ser Lys Leu Val Gln# 15450- AAC ATC ATC CAG ACA GCC GTT GAC CAG TTT GT - #A CGT ACA GAA GAA ACA4886Asn Ile Ile Gln Thr Ala Val Asp Gln Phe Va - #l Arg Thr Glu Glu Thr# 15651555 - # 1560- GCC ACC GAA ATG TTG ACG TCT GAG TTA CAG AC - #A CAA GCT CAC GTG ATA4934Ala Thr Glu Met Leu Thr Ser Glu Leu Gln Th - #r Gln Ala His Val Ile# 15805- AAA GCT GAC AGC CAG GAC GCT GGA CAG GAA AC - #G GAG AAA GAA GGA GAG4982Lys Ala Asp Ser Gln Asp Ala Gly Gln Glu Th - #r Glu Lys Glu Gly Glu# 15950- GAA CCT CAG GCC TCT GCA CAG GAT GAA ACA CC - #A ATT ACT TCA GCC AAA5030Glu Pro Gln Ala Ser Ala Gln Asp Glu Thr Pr - #o Ile Thr Ser Ala Lys# 16105- GAG GAG TCA GAG TCA ACC GCA GTG GGA CAA GC - #A CAT TCT GAT ATT TCC5078Glu Glu Ser Glu Ser Thr Ala Val Gly Gln Al - #a His Ser Asp Ile Ser# 16250- AAA GAC ATG AGT GAA GCC TCA GAA AAG ACC AT - #G ACT GTT GAG GTA GAA5126Lys Asp Met Ser Glu Ala Ser Glu Lys Thr Me - #t Thr Val Glu Val Glu# 16451635 - # 1640- GGT TCC ACT GTA AAT GAT CAG CAG CTG GAA GA - #G GTC GTC CTC CCA TCT5174Gly Ser Thr Val Asn Asp Gln Gln Leu Glu Gl - #u Val Val Leu Pro Ser# 16605- GAG GAA GAG GGA GGT GGA GCT GGA ACA AAG TC - #T GTG CCA GAA GAT GAT5222Glu Glu Glu Gly Gly Gly Ala Gly Thr Lys Se - #r Val Pro Glu Asp Asp# 16750- GGT CAT GCC TTG TTA GCA GAA AGA ATA GAG AA - #G TCA CTA GTT GAA CCG5270Gly His Ala Leu Leu Ala Glu Arg Ile Glu Ly - #s Ser Leu Val Glu Pro# 16905- AAA GAA GAT GAA AAA GGT GAT GAT GTT GAT GA - #C CCT GAA AAC CAG AAC5318Lys Glu Asp Glu Lys Gly Asp Asp Val Asp As - #p Pro Glu Asn Gln Asn# 17050- TCA GCC CTG GCT GAT ACT GAT GCC TCA GGA GG - #C TTA ACC AAA GAG TCC5366Ser Ala Leu Ala Asp Thr Asp Ala Ser Gly Gl - #y Leu Thr Lys Glu Ser# 17251715 - # 1720- CCA GAT ACA AAT GGA CCA AAA CAA AAA GAG AA - #G GAG GAT GCC CAG GAA5414Pro Asp Thr Asn Gly Pro Lys Gln Lys Glu Ly - #s Glu Asp Ala Gln Glu# 17405- GTA GAA TTG CAG GAA GGA AAA GTG CAC AGT GA - #A TCA GAT AAA GCG ATC5462Val Glu Leu Gln Glu Gly Lys Val His Ser Gl - #u Ser Asp Lys Ala Ile# 17550- ACA CCC CAA GCA CAG GAG GAG TTA CAG AAA CA - #A GAG AGA GAA TCT GCA5510Thr Pro Gln Ala Gln Glu Glu Leu Gln Lys Gl - #n Glu Arg Glu Ser Ala# 17705- AAG TCA GAA CTT ACA GAA TCT TAAAACATCA TGCAGTTAA - #A CTCATTGTCT5561Lys Ser Glu Leu Thr Glu Ser# 1780- GTTTGGAAGA CCAGAATGTG AAGACAAGTA GTAGAAGAAA ATGAATGCTG CT - #GCTGAGAC5621- TGAAGACCAG TATTTCAGAA CTTTGAGAAT TGGAGAGCAG GCACATCAAC TG - #ATCTCATT5681- TCTAGAGAGC CCCTGACAAT CCTGAGGCTT CATCAGGAGC TAGAGCCATT TA - #ACATTTCC5741- TCTTTCCAAG ACCAACCTAC AATTTTCCCT TGATAACCAT ATAAATTCTG AT - #TTAAGGTC5801- CTAAATTCTT AACCTGGAAC TGGAGTTGGC AATACCTAGT TCTGCTTCTG AA - #ACTGGAGT5861- ATCATTCTTT ACATATTTAT ATGTATGTTT TAAGTAGTCC TCCTGTATCT AT - #TGTATATT5921- TTTTTCTTAA TGTTTAAGGA AATGTGCAGG ATACTACATG CTTTTTGTAT CA - #CACAGTAT5981- ATGATGGGGC ATGTGCCATA GTGCAGGCTT GGGGAGCTTT AAGCCTCAGT TA - #TATAACCC6041- ACAAAAAACA GAGCCTCCTA GATGTAACAT TCCTGATCAA GGTACAATTC TT - #TAAAATTC6101- ACTAATGATT GAGGTCCATA TTTAGTGGTA CTCTGAAATT GGTCACTTTC CT - #ATTACACG6161- GAGTGTGCCA AAACTAAAAA GCATTTTGAA ACATACAGAA TGTTCTATTG TC - #ATTGGGAA6221- ATTTTGCTTT CTAACCCAGT GGAGGTTAGA AAGAAGTTAT ATTCTGGTAG CA - #AATTAACT6281- TTACATCCTT TTTCCTACTT GTTATGGTTG TTTGGACCGA TAAGTGTGCT TA - #ATCCTGAG6341- GCAAAGTAGT GAATATGTTT TATATGTTAT GAAGAAAAGA ATTGTTGTAA GT - #TTTTGATT6401- CTACTCTTAT ATGCTGGACT GCATTCACAC ATGGCATGAA ATAAGTCAGG TT - #CTTTACAA6461- ATGGTATTTT GATAGATACT GGATTGTGTT TGTGCCATAT TTGTGCCATT CC - #TTTAAGAA6521- CAATGTTGCA ACACATTCAT TTGGATAAGT TGTGATTTGA CGACTGATTT AA - #ATAAAATA6581# 6605AAAA AAAA- (2) INFORMATION FOR SEQ ID NO:5:- (i) SEQUENCE CHARACTERISTICS:#acids (A) LENGTH: 1780 amino (B) TYPE: amino acid (D) TOPOLOGY: linear- (ii) MOLECULE TYPE: protein- (xi) SEQUENCE DESCRIPTION: SEQ ID NO:5:- Met Gly Ala Gly Ser Ser Thr Glu Gln Arg Se - #r Pro Glu Gln Pro Pro# 15- Glu Gly Ser Ser Thr Pro Ala Glu Pro Glu Pr - #o Ser Gly Gly Gly Pro# 30- Ser Ala Glu Ala Ala Pro Asp Thr Thr Ala As - #p Pro Ala Ile Ala Ala# 45- Ser Asp Pro Ala Thr Lys Leu Leu Gln Lys As - #n Gly Gln Leu Ser Thr# 60- Ile Asn Gly Val Ala Glu Gln Asp Glu Leu Se - #r Leu Gln Glu Gly Asp# 80- Leu Asn Gly Gln Lys Gly Ala Leu Asn Gly Gl - #n Gly Ala Leu Asn Ser# 95- Gln Glu Glu Glu Glu Val Ile Val Thr Glu Va - #l Gly Gln Arg Asp Ser# 110- Glu Asp Val Ser Glu Arg Asp Ser Asp Lys Gl - #u Met Ala Thr Lys Ser# 125- Ala Val Val His Asp Ile Thr Asp Asp Gly Gl - #n Glu Glu Asn Arg Asn# 140- Ile Glu Gln Ile Pro Ser Ser Glu Ser Asn Le - #u Glu Glu Leu Thr Gln145 1 - #50 1 - #55 1 -#60- Pro Thr Glu Ser Gln Ala Asn Asp Ile Gly Ph - #e Lys Lys Val Phe Lys# 175- Phe Val Gly Phe Lys Phe Thr Val Lys Lys As - #p Lys Thr Glu Lys Pro# 190- Asp Thr Val Gln Leu Leu Thr Val Lys Lys As - #p Glu Gly Glu Gly Ala# 205- Ala Gly Ala Gly Asp His Gln Asp Pro Ser Le - #u Gly Ala Gly Glu Ala# 220- Ala Ser Lys Glu Ser Glu Pro Lys Gln Ser Th - #r Glu Lys Pro Glu Glu225 2 - #30 2 - #35 2 -#40- Thr Leu Lys Arg Glu Gln Ser His Ala Glu Il - #e Ser Pro Pro Ala Glu# 255- Ser Gly Gln Ala Val Glu Glu Cys Lys Glu Gl - #u Gly Glu Glu Lys Gln# 270- Glu Lys Glu Pro Ser Lys Ser Ala Glu Ser Pr - #o Thr Ser Pro Val Thr# 285- Ser Glu Thr Gly Ser Thr Phe Lys Lys Phe Ph - #e Thr Gln Gly Trp Ala# 300- Gly Trp Arg Lys Lys Thr Ser Phe Arg Lys Pr - #o Lys Glu Asp Glu Val305 3 - #10 3 - #15 3 -#20- Glu Ala Ser Glu Lys Lys Lys Glu Gln Glu Pr - #o Glu Lys Val Asp Thr# 335- Glu Glu Asp Gly Lys Ala Glu Val Ala Ser Gl - #u Lys Leu Thr Ala Ser# 350- Glu Gln Ala His Pro Gln Glu Pro Ala Glu Se - #r Ala His Glu Pro Arg# 365- Leu Ser Ala Glu Tyr Glu Lys Val Glu Leu Pr - #o Ser Glu Glu Gln Val# 380- Ser Gly Ser Gln Gly Pro Ser Glu Glu Lys Pr - #o Ala Pro Leu Ala Thr385 3 - #90 3 - #95 4 -#00- Glu Val Phe Asp Glu Lys Ile Glu Val His Gl - #n Glu Glu Val Val Ala# 415- Glu Val His Val Ser Thr Val Glu Glu Arg Th - #r Glu Glu Gln Lys Thr# 430- Glu Val Glu Glu Thr Ala Gly Ser Val Pro Al - #a Glu Glu Leu Val Gly# 445- Met Asp Ala Glu Pro Gln Glu Ala Glu Pro Al - #a Lys Glu Leu Val Lys# 460- Leu Lys Glu Thr Cys Val Ser Gly Glu Asp Pr - #o Thr Gln Gly Ala Asp465 4 - #70 4 - #75 4 -#80- Leu Ser Pro Asp Glu Lys Val Leu Ser Lys Pr - #o Pro Glu Gly Val Val# 495- Ser Glu Val Glu Met Leu Ser Ser Gln Glu Ar - #g Met Lys Val Gln Gly# 510- Ser Pro Leu Lys Lys Leu Phe Thr Ser Thr Gl - #y Leu Lys Lys Leu Ser# 525- Gly Lys Lys Gln Lys Gly Lys Arg Gly Gly Gl - #y Asp Glu Glu Ser Gly# 540- Glu His Thr Gln Val Pro Ala Asp Ser Pro As - #p Ser Gln Glu Glu Gln545 5 - #50 5 - #55 5 -#60- Lys Gly Glu Ser Ser Ala Ser Ser Pro Glu Gl - #u Pro Glu Glu Ile Thr# 575- Cys Leu Glu Lys Gly Leu Ala Glu Val Gln Gl - #n Asp Gly Glu Ala Glu# 590- Glu Gly Ala Thr Ser Asp Gly Glu Lys Lys Ar - #g Glu Gly Val Thr Pro# 605- Trp Ala Ser Phe Lys Lys Met Val Thr Pro Ly - #s Lys Arg Val Arg Arg# 620- Pro Ser Glu Ser Asp Lys Glu Asp Glu Leu As - #p Lys Val Lys Ser Ala625 6 - #30 6 - #35 6 -#40- Thr Leu Ser Ser Thr Glu Ser Thr Ala Ser Gl - #u Met Gln Glu Glu Met# 655- Lys Gly Ser Val Glu Glu Pro Lys Pro Glu Gl - #u Pro Lys Arg Lys Val# 670- Asp Thr Ser Val Ser Trp Glu Ala Leu Ile Cy - #s Val Gly Ser Ser Lys# 685- Lys Arg Ala Arg Arg Arg Ser Ser Ser Asp Gl - #u Glu Gly Gly Pro Lys# 700- Ala Met Gly Gly Asp His Gln Lys Ala Asp Gl - #u Ala Gly Lys Asp Lys705 7 - #10 7 - #15 7 -#20- Glu Thr Gly Thr Asp Gly Ile Leu Ala Gly Se - #r Gln Glu His Asp Pro# 735- Gly Gln Gly Ser Ser Ser Pro Glu Gln Ala Gl - #y Ser Pro Thr Glu Gly# 750- Glu Gly Val Ser Thr Trp Glu Ser Phe Lys Ar - #g Leu Val Thr Pro Arg# 765- Lys Lys Ser Lys Ser Lys Leu Glu Glu Lys Se - #r Glu Asp Ser Ile Ala# 780- Gly Ser Gly Val Glu His Ser Thr Pro Asp Th - #r Glu Pro Gly Lys Glu785 7 - #90 7 - #95 8 -#00- Glu Ser Trp Val Ser Ile Lys Lys Phe Ile Pr - #o Gly Arg Arg Lys Lys# 815- Arg Pro Asp Gly Lys Gln Glu Gln Ala Pro Va - #l Glu Asp Ala Gly Pro# 830- Thr Gly Ala Asn Glu Asp Asp Ser Asp Val Pr - #o Ala Val Val Pro Leu# 845- Ser Glu Tyr Asp Ala Val Glu Arg Glu Lys Me - #t Glu Ala Gln Gln Ala# 860- Gln Lys Gly Ala Glu Gln Pro Glu Gln Lys Al - #a Ala Thr Glu Val Ser865 8 - #70 8 - #75 8 -#80- Lys Glu Leu Ser Glu Ser Gln Val His Met Me - #t Ala Ala Ala Val Ala# 895- Asp Gly Thr Arg Ala Ala Thr Ile Ile Glu Gl - #u Arg Ser Pro Ser Trp# 910- Ile Ser Ala Ser Val Thr Glu Pro Leu Glu Gl - #n Val Glu Ala Glu Ala# 925- Ala Leu Leu Thr Glu Glu Val Leu Glu Arg Gl - #u Val Ile Ala Glu Glu# 940- Glu Pro Pro Thr Val Thr Glu Pro Leu Pro Gl - #u Asn Arg Glu Ala Arg945 9 - #50 9 - #55 9 -#60- Gly Asp Thr Val Val Ser Glu Ala Glu Leu Th - #r Pro Glu Ala Val Thr# 975- Ala Ala Glu Thr Ala Gly Pro Leu Gly Ser Gl - #u Glu Gly Thr Glu Ala# 990- Ser Ala Ala Glu Glu Thr Thr Glu Met Val Se - #r Ala Val Ser Gln Leu# 10050- Thr Asp Ser Pro Asp Thr Thr Glu Glu Ala Th - #r Pro Val Gln Glu Val# 10205- Glu Gly Gly Val Pro Asp Ile Glu Glu Gln Gl - #u Arg Arg Thr Gln Glu# 10401030 - # 1035- Val Leu Gln Ala Val Ala Glu Lys Val Lys Gl - #u Glu Ser Gln Leu Pro# 10550- Gly Thr Gly Gly Pro Glu Asp Val Leu Gln Pr - #o Val Gln Arg Ala Glu# 10705- Ala Glu Arg Pro Glu Glu Gln Ala Glu Ala Se - #r Gly Leu Lys Lys Glu# 10850- Thr Asp Val Val Leu Lys Val Asp Ala Gln Gl - #u Ala Lys Thr Glu Pro# 11005- Phe Thr Gln Gly Lys Val Val Gly Gln Thr Th - #r Pro Glu Ser Phe Glu# 11201110 - # 1115- Lys Ala Pro Gln Val Thr Glu Ser Ile Glu Se - #r Ser Glu Leu Val Thr# 11350- Thr Cys Gln Ala Glu Thr Leu Ala Gly Val Ly - #s Ser Gln Glu Met Val# 11505- Met Glu Gln Ala Ile Pro Pro Asp Ser Val Gl - #u Thr Pro Thr Asp Ser# 11650- Glu Thr Asp Gly Ser Thr Pro Val Ala Asp Ph - #e Asp Ala Pro Gly Thr# 11805- Thr Gln Lys Asp Glu Ile Val Glu Ile His Gl - #u Glu Asn Glu Val His# 12001190 - # 1195- Leu Val Pro Val Arg Gly Thr Glu Ala Glu Al - #a Val Pro Ala Gln Lys# 12150- Glu Arg Pro Pro Ala Pro Ser Ser Phe Val Ph - #e Gln Glu Glu Thr Lys# 12305- Glu Gln Ser Lys Met Glu Asp Thr Leu Glu Hi - #s Thr Asp Lys Glu Val# 12450- Ser Val Glu Thr Val Ser Ile Leu Ser Lys Th - #r Glu Gly Thr Gln Glu# 12605- Ala Asp Gln Tyr Ala Asp Glu Lys Thr Lys As - #p Val Pro Phe Phe Glu# 12801270 - # 1275- Gly Leu Glu Gly Ser Ile Asp Thr Gly Ile Th - #r Val Ser Arg Glu Lys# 12950- Val Thr Glu Val Ala Leu Lys Gly Glu Gly Th - #r Glu Glu Ala Glu Cys# 13105- Lys Lys Asp Asp Ala Leu Glu Leu Gln Ser Hi - #s Ala Lys Ser Pro Pro# 13250- Ser Pro Val Glu Arg Glu Met Val Val Gln Va - #l Glu Arg Glu Lys Thr# 13405- Glu Ala Glu Pro Thr His Val Asn Glu Glu Ly - #s Leu Glu His Glu Thr# 13601350 - # 1355- Ala Val Thr Val Ser Glu Glu Val Ser Lys Gl - #n Leu Leu Gln Thr Val# 13750- Asn Val Pro Ile Ile Asp Gly Ala Lys Glu Va - #l Ser Ser Leu Glu Gly# 13905- Ser Pro Pro Pro Cys Leu Gly Gln Glu Glu Al - #a Val Cys Thr Lys Ile# 14050- Gln Val Gln Ser Ser Glu Ala Ser Phe Thr Le - #u Thr Ala Ala Ala Glu# 14205- Glu Glu Lys Val Leu Gly Glu Thr Ala Asn Il - #e Leu Glu Thr Gly Glu# 14401430 - # 1435- Thr Leu Glu Pro Ala Gly Ala His Leu Val Le - #u Glu Glu Lys Ser Ser# 14550- Glu Lys Asn Glu Asp Phe Ala Ala His Pro Gl - #y Glu Asp Ala Val Pro# 14705- Thr Gly Pro Asp Cys Gln Ala Lys Ser Thr Pr - #o Val Ile Val Ser Ala# 14850- Thr Thr Lys Lys Gly Leu Ser Ser Asp Leu Gl - #u Gly Glu Lys Thr Thr# 15005- Ser Leu Lys Trp Lys Ser Asp Glu Val Asp Gl - #u Gln Val Ala Cys Gln# 15201510 - # 1515- Glu Val Lys Val Ser Val Ala Ile Glu Asp Le - #u Glu Pro Glu Asn Gly# 15350- Ile Leu Glu Leu Glu Thr Lys Ser Ser Lys Le - #u Val Gln Asn Ile Ile# 15505- Gln Thr Ala Val Asp Gln Phe Val Arg Thr Gl - #u Glu Thr Ala Thr Glu# 15650- Met Leu Thr Ser Glu Leu Gln Thr Gln Ala Hi - #s Val Ile Lys Ala Asp# 15805- Ser Gln Asp Ala Gly Gln Glu Thr Glu Lys Gl - #u Gly Glu Glu Pro Gln# 16001590 - # 1595- Ala Ser Ala Gln Asp Glu Thr Pro Ile Thr Se - #r Ala Lys Glu Glu Ser# 16150- Glu Ser Thr Ala Val Gly Gln Ala His Ser As - #p Ile Ser Lys Asp Met# 16305- Ser Glu Ala Ser Glu Lys Thr Met Thr Val Gl - #u Val Glu Gly Ser Thr# 16450- Val Asn Asp Gln Gln Leu Glu Glu Val Val Le - #u Pro Ser Glu Glu Glu# 16605- Gly Gly Gly Ala Gly Thr Lys Ser Val Pro Gl - #u Asp Asp Gly His Ala# 16801670 - # 1675- Leu Leu Ala Glu Arg Ile Glu Lys Ser Leu Va - #l Glu Pro Lys Glu Asp# 16950- Glu Lys Gly Asp Asp Val Asp Asp Pro Glu As - #n Gln Asn Ser Ala Leu# 17105- Ala Asp Thr Asp Ala Ser Gly Gly Leu Thr Ly - #s Glu Ser Pro Asp Thr# 17250- Asn Gly Pro Lys Gln Lys Glu Lys Glu Asp Al - #a Gln Glu Val Glu Leu# 17405- Gln Glu Gly Lys Val His Ser Glu Ser Asp Ly - #s Ala Ile Thr Pro Gln# 17601750 - # 1755- Ala Gln Glu Glu Leu Gln Lys Gln Glu Arg Gl - #u Ser Ala Lys Ser Glu# 17750- Leu Thr Glu Ser 1780- (2) INFORMATION FOR SEQ ID NO:6:- (i) SEQUENCE CHARACTERISTICS:#acids (A) LENGTH: 14 amino (B) TYPE: amino acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear- (xi) SEQUENCE DESCRIPTION: SEQ ID NO:6:- Leu Glu Thr Lys Ser Ser Lys Leu Val Gln As - #n Ile Ile Gln# 10- (2) INFORMATION FOR SEQ ID NO:7:- (i) SEQUENCE CHARACTERISTICS:#acids (A) LENGTH: 14 amino (B) TYPE: amino acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear- (xi) SEQUENCE DESCRIPTION: SEQ ID NO:7:- Leu Ile Glu Thr Ala Ser Ser Leu Val Lys As - #n Ala Ile Gln# 10- (2) INFORMATION FOR SEQ ID NO:8:- (i) SEQUENCE CHARACTERISTICS:#acids (A) LENGTH: 23 amino (B) TYPE: amino acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear- (xi) SEQUENCE DESCRIPTION: SEQ ID NO:8:- Asp Leu Ile Glu Glu Ala Ala Ser Arg Ile Va - #l Asp Ala Val Ile# 15- Glu Gln Val Lys Ala Ala Gly Ala 20- (2) INFORMATION FOR SEQ ID NO:9:- (i) SEQUENCE CHARACTERISTICS:#pairs (A) LENGTH: 33 base (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear- (xi) SEQUENCE DESCRIPTION: SEQ ID NO:9:# 33 GTCC GAGTCCAGTG AGC- (2) INFORMATION FOR SEQ ID NO:10:- (i) SEQUENCE CHARACTERISTICS:#pairs (A) LENGTH: 30 base (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear- (xi) SEQUENCE DESCRIPTION: SEQ ID NO:10:# 30 ACTT TGACCTCCTG- (2) INFORMATION FOR SEQ ID NO:11:- (i) SEQUENCE CHARACTERISTICS:#pairs (A) LENGTH: 30 base (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear- (xi) SEQUENCE DESCRIPTION: SEQ ID NO:11:# 30 ACGT GAGCTTGTGT- (2) INFORMATION FOR SEQ ID NO:12:- (i) SEQUENCE CHARACTERISTICS:#pairs (A) LENGTH: 36 base (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear- (xi) SEQUENCE DESCRIPTION: SEQ ID NO:12:# 36 GGTA GCAATTGAGG ATTTAG- (2) INFORMATION FOR SEQ ID NO:13:- (i) SEQUENCE CHARACTERISTICS:#pairs (A) LENGTH: 27 base (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear- (xi) SEQUENCE DESCRIPTION: SEQ ID NO:13:# 27 CTGT AGTTCTG- (2) INFORMATION FOR SEQ ID NO:14:- (i) SEQUENCE CHARACTERISTICS:#acids (A) LENGTH: 453 amino (B) TYPE: amino acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear- (xi) SEQUENCE DESCRIPTION: SEQ ID NO:14:- Glu Ser Ser Glu Leu Val Thr Thr Cys Gln Al - #a Glu Thr Leu Ala Gly# 15- Val Lys Ser Gln Glu Met Val Met Glu Gln Al - #a Ile Pro Pro Asp Ser# 30- Val Glu Thr Pro Thr Asp Ser Glu Thr Asp Gl - #y Ser Thr Pro Val Ala# 45- Asp Phe Asp Ala Pro Gly Thr Thr Gln Lys As - #p Glu Ile Val Glu Ile# 60- His Glu Glu Asn Glu Val His Leu Val Pro Va - #l Arg Gly Thr Glu Ala#80- Glu Ala Val Pro Ala Gln Lys Glu Arg Pro Pr - #o Ala Pro Ser Ser Phe# 95- Val Phe Gln Glu Glu Thr Lys Glu Gln Ser Ly - #s Met Glu Asp Thr Leu# 110- Glu His Thr Asp Lys Glu Val Ser Val Glu Th - #r Val Ser Ile Leu Ser# 125- Lys Thr Glu Gly Thr Gln Glu Ala Asp Gln Ty - #r Ala Asp Glu Lys Thr# 140- Lys Asp Val Pro Phe Phe Glu Gly Leu Glu Gl - #y Ser Ile Asp Thr Gly145 1 - #50 1 - #55 1 -#60- Ile Thr Val Ser Arg Glu Lys Val Thr Glu Va - #l Ala Leu Lys Gly Glu# 175- Gly Thr Glu Glu Ala Glu Cys Lys Lys Asp As - #p Ala Leu Glu Leu Gln# 190- Ser His Ala Lys Ser Pro Pro Ser Pro Val Gl - #u Arg Glu Met Val Val# 205- Gln Val Glu Arg Glu Lys Thr Glu Ala Glu Pr - #o Thr His Val Asn Glu# 220- Glu Lys Leu Glu His Glu Thr Ala Val Thr Va - #l Ser Glu Glu Val Ser225 2 - #30 2 - #35 2 -#40- Lys Gln Leu Leu Gln Thr Val Asn Val Pro Il - #e Ile Asp Gly Ala Lys# 255- Glu Val Ser Ser Leu Glu Gly Ser Pro Pro Pr - #o Cys Leu Gly Gln Glu# 270- Glu Ala Val Cys Thr Lys Ile Gln Val Gln Se - #r Ser Glu Ala Ser Phe# 285- Thr Leu Thr Ala Ala Ala Glu Glu Glu Lys Va - #l Leu Gly Glu Thr Ala# 300- Asn Ile Leu Glu Thr Gly Glu Thr Leu Glu Pr - #o Ala Gly Ala His Leu305 3 - #10 3 - #15 3 -#20- Val Leu Glu Glu Lys Ser Ser Glu Lys Asn Gl - #u Asp Phe Ala Ala His# 335- Pro Gly Glu Asp Ala Val Pro Thr Gly Pro As - #p Cys Gln Ala Lys Ser# 350- Thr Pro Val Ile Val Ser Ala Thr Thr Lys Ly - #s Gly Leu Ser Ser Asp# 365- Leu Glu Gly Glu Lys Thr Thr Ser Leu Lys Tr - #p Lys Ser Asp Glu Val# 380- Asp Glu Gln Val Ala Cys Gln Glu Val Lys Va - #l Ser Val Ala Ile Glu385 3 - #90 3 - #95 4 -#00- Asp Leu Glu Pro Glu Asn Gly Ile Leu Glu Le - #u Glu Thr Lys Ser Ser# 415- Lys Leu Val Gln Asn Ile Ile Gln Thr Ala Va - #l Asp Gln Phe Val Arg# 430- Thr Glu Glu Thr Ala Thr Glu Met Leu Thr Se - #r Glu Leu Gln Thr Gln# 445- Ala His Val Ile Lys 450- (2) INFORMATION FOR SEQ ID NO:15:- (i) SEQUENCE CHARACTERISTICS:#acids (A) LENGTH: 396 amino (B) TYPE: amino acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear- (xi) SEQUENCE DESCRIPTION: SEQ ID NO:15:- Glu Ser Ser Glu Leu Val Thr Thr Cys Gln Al - #a Glu Thr Leu Ala Gly# 15- Val Lys Ser Gln Glu Met Val Met Glu Gln Al - #a Ile Pro Pro Asp Ser# 30- Val Glu Thr Pro Thr Asp Ser Glu Thr Asp Gl - #y Ser Thr Pro Val Ala# 45- Asp Phe Asp Ala Pro Gly Thr Thr Gln Lys As - #p Glu Ile Val Glu Ile# 60- His Glu Glu Asn Glu Val His Leu Val Pro Va - #l Arg Gly Thr Glu Ala#80- Glu Ala Val Pro Ala Gln Lys Glu Arg Pro Pr - #o Ala Pro Ser Ser Phe# 95- Val Phe Gln Glu Glu Thr Lys Glu Gln Ser Ly - #s Met Glu Asp Thr Leu# 110- Glu His Thr Asp Lys Glu Val Ser Val Glu Th - #r Val Ser Ile Leu Ser# 125- Lys Thr Glu Gly Thr Gln Glu Ala Asp Gln Ty - #r Ala Asp Glu Lys Thr# 140- Lys Asp Val Pro Phe Phe Glu Gly Leu Glu Gl - #y Ser Ile Asp Thr Gly145 1 - #50 1 - #55 1 -#60- Ile Thr Val Ser Arg Glu Lys Val Thr Glu Va - #l Ala Leu Lys Gly Glu# 175- Gly Thr Glu Glu Ala Glu Cys Lys Lys Asp As - #p Ala Leu Glu Leu Gln# 190- Ser His Ala Lys Ser Pro Pro Ser Pro Val Gl - #u Arg Glu Met Val Val# 205- Gln Val Glu Arg Glu Lys Thr Glu Ala Glu Pr - #o Thr His Val Asn Glu# 220- Glu Lys Leu Glu His Glu Thr Ala Val Thr Va - #l Ser Glu Glu Val Ser225 2 - #30 2 - #35 2 -#40- Lys Gln Leu Leu Gln Thr Val Asn Val Pro Il - #e Ile Asp Gly Ala Lys# 255- Glu Val Ser Ser Leu Glu Gly Ser Pro Pro Pr - #o Cys Leu Gly Gln Glu# 270- Glu Ala Val Cys Thr Lys Ile Gln Val Gln Se - #r Ser Glu Ala Ser Phe# 285- Thr Leu Thr Ala Ala Ala Glu Glu Glu Lys Va - #l Leu Gly Glu Thr Ala# 300- Asn Ile Leu Glu Thr Gly Glu Thr Leu Glu Pr - #o Ala Gly Ala His Leu305 3 - #10 3 - #15 3 -#20- Val Leu Glu Glu Lys Ser Ser Glu Lys Asn Gl - #u Asp Phe Ala Ala His# 335- Pro Gly Glu Asp Ala Val Pro Thr Gly Pro As - #p Cys Gln Ala Lys Ser# 350- Thr Pro Val Ile Val Ser Ala Thr Thr Lys Ly - #s Gly Leu Ser Ser Asp# 365- Leu Glu Gly Glu Lys Thr Thr Ser Leu Lys Tr - #p Lys Ser Asp Glu Val# 380- Asp Glu Gln Val Ala Cys Gln Glu Val Lys Va - #l Ser385 3 - #90 3 - #95- (2) INFORMATION FOR SEQ ID NO:16:- (i) SEQUENCE CHARACTERISTICS:#acids (A) LENGTH: 255 amino (B) TYPE: amino acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear- (xi) SEQUENCE DESCRIPTION: SEQ ID NO:16:- Val Ala Ile Glu Asp Leu Glu Pro Glu Asn Gl - #y Ile Leu Glu Leu Glu# 15- Thr Lys Ser Ser Lys Leu Val Gln Asn Ile Il - #e Gln Thr Ala Val Asp# 30- Gln Phe Val Arg Thr Glu Glu Thr Ala Thr Gl - #u Met Leu Thr Ser Glu# 45- Leu Gln Thr Gln Ala His Val Ile Lys Ala As - #p Ser Gln Asp Ala Gly# 60- Gln Glu Thr Glu Lys Glu Gly Glu Glu Pro Gl - #n Ala Ser Ala Gln Asp#80- Glu Thr Pro Ile Thr Ser Ala Lys Glu Glu Se - #r Glu Ser Thr Ala Val# 95- Gly Gln Ala His Ser Asp Ile Ser Lys Asp Me - #t Ser Glu Ala Ser Glu# 110- Lys Thr Met Thr Val Glu Val Glu Gly Ser Th - #r Val Asn Asp Gln Gln# 125- Leu Glu Glu Val Val Leu Pro Ser Glu Glu Gl - #u Gly Gly Gly Ala Gly# 140- Thr Lys Ser Val Pro Glu Asp Asp Gly His Al - #a Leu Leu Ala Glu Arg145 1 - #50 1 - #55 1 -#60- Ile Glu Lys Ser Leu Val Glu Pro Lys Glu As - #p Glu Lys Gly Asp Asp# 175- Val Asp Asp Pro Glu Asn Gln Asn Ser Ala Le - #u Ala Asp Thr Asp Ala# 190- Ser Gly Gly Leu Thr Lys Glu Ser Pro Asp Th - #r Asn Gly Pro Lys Gln# 205- Lys Glu Lys Glu Asp Ala Gln Glu Val Glu Le - #u Gln Glu Gly Lys Val# 220- His Ser Glu Ser Asp Lys Ala Ile Thr Pro Gl - #n Ala Gln Glu Glu Leu225 2 - #30 2 - #35 2 -#40- Gln Lys Gln Glu Arg Glu Ser Ala Lys Ser Gl - #u Leu Thr Glu Ser# 255- (2) INFORMATION FOR SEQ ID NO:17:- (i) SEQUENCE CHARACTERISTICS:#acids (A) LENGTH: 651 amino (B) TYPE: amino acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear- (xi) SEQUENCE DESCRIPTION: SEQ ID NO:17:- Glu Ser Ser Glu Leu Val Thr Thr Cys Gln Al - #a Glu Thr Leu Ala Gly# 15- Val Lys Ser Gln Glu Met Val Met Glu Gln Al - #a Ile Pro Pro Asp Ser# 30- Val Glu Thr Pro Thr Asp Ser Glu Thr Asp Gl - #y Ser Thr Pro Val Ala# 45- Asp Phe Asp Ala Pro Gly Thr Thr Gln Lys As - #p Glu Ile Val Glu Ile# 60- His Glu Glu Asn Glu Val His Leu Val Pro Va - #l Arg Gly Thr Glu Ala#80- Glu Ala Val Pro Ala Gln Lys Glu Arg Pro Pr - #o Ala Pro Ser Ser Phe# 95- Val Phe Gln Glu Glu Thr Lys Glu Gln Ser Ly - #s Met Glu Asp Thr Leu# 110- Glu His Thr Asp Lys Glu Val Ser Val Glu Th - #r Val Ser Ile Leu Ser# 125- Lys Thr Glu Gly Thr Gln Glu Ala Asp Gln Ty - #r Ala Asp Glu Lys Thr# 140- Lys Asp Val Pro Phe Phe Glu Gly Leu Glu Gl - #y Ser Ile Asp Thr Gly145 1 - #50 1 - #55 1 -#60- Ile Thr Val Ser Arg Glu Lys Val Thr Glu Va - #l Ala Leu Lys Gly Glu# 175- Gly Thr Glu Glu Ala Glu Cys Lys Lys Asp As - #p Ala Leu Glu Leu Gln# 190- Ser His Ala Lys Ser Pro Pro Ser Pro Val Gl - #u Arg Glu Met Val Val# 205- Gln Val Glu Arg Glu Lys Thr Glu Ala Glu Pr - #o Thr His Val Asn Glu# 220- Glu Lys Leu Glu His Glu Thr Ala Val Thr Va - #l Ser Glu Glu Val Ser225 2 - #30 2 - #35 2 -#40- Lys Gln Leu Leu Gln Thr Val Asn Val Pro Il - #e Ile Asp Gly Ala Lys# 255- Glu Val Ser Ser Leu Glu Gly Ser Pro Pro Pr - #o Cys Leu Gly Gln Glu# 270- Glu Ala Val Cys Thr Lys Ile Gln Val Gln Se - #r Ser Glu Ala Ser Phe# 285- Thr Leu Thr Ala Ala Ala Glu Glu Glu Lys Va - #l Leu Gly Glu Thr Ala# 300- Asn Ile Leu Glu Thr Gly Glu Thr Leu Glu Pr - #o Ala Gly Ala His Leu305 3 - #10 3 - #15 3 -#20- Val Leu Glu Glu Lys Ser Ser Glu Lys Asn Gl - #u Asp Phe Ala Ala His# 335- Pro Gly Glu Asp Ala Val Pro Thr Gly Pro As - #p Cys Gln Ala Lys Ser# 350- Thr Pro Val Ile Val Ser Ala Thr Thr Lys Ly - #s Gly Leu Ser Ser Asp# 365- Leu Glu Gly Glu Lys Thr Thr Ser Leu Lys Tr - #p Lys Ser Asp Glu Val# 380- Asp Glu Gln Val Ala Cys Gln Glu Val Lys Va - #l Ser Val Ala Ile Glu385 3 - #90 3 - #95 4 -#00- Asp Leu Glu Pro Glu Asn Gly Ile Leu Glu Le - #u Glu Thr Lys Ser Ser# 415- Lys Leu Val Gln Asn Ile Ile Gln Thr Ala Va - #l Asp Gln Phe Val Arg# 430- Thr Glu Glu Thr Ala Thr Glu Met Leu Thr Se - #r Glu Leu Gln Thr Gln# 445- Ala His Val Ile Lys Ala Asp Ser Gln Asp Al - #a Gly Gln Glu Thr Glu# 460- Lys Glu Gly Glu Glu Pro Gln Ala Ser Ala Gl - #n Asp Glu Thr Pro Ile465 4 - #70 4 - #75 4 -#80- Thr Ser Ala Lys Glu Glu Ser Glu Ser Thr Al - #a Val Gly Gln Ala His# 495- Ser Asp Ile Ser Lys Asp Met Ser Glu Ala Se - #r Glu Lys Thr Met Thr# 510- Val Glu Val Glu Gly Ser Thr Val Asn Asp Gl - #n Gln Leu Glu Glu Val# 525- Val Leu Pro Ser Glu Glu Glu Gly Gly Gly Al - #a Gly Thr Lys Ser Val# 540- Pro Glu Asp Asp Gly His Ala Leu Leu Ala Gl - #u Arg Ile Glu Lys Ser545 5 - #50 5 - #55 5 -#60- Leu Val Glu Pro Lys Glu Asp Glu Lys Gly As - #p Asp Val Asp Asp Pro# 575- Glu Asn Gln Asn Ser Ala Leu Ala Asp Thr As - #p Ala Ser Gly Gly Leu# 590- Thr Lys Glu Ser Pro Asp Thr Asn Gly Pro Ly - #s Gln Lys Glu Lys Glu# 605- Asp Ala Gln Glu Val Glu Leu Gln Glu Gly Ly - #s Val His Ser Glu Ser# 620- Asp Lys Ala Ile Thr Pro Gln Ala Gln Glu Gl - #u Leu Gln Lys Gln Glu625 6 - #30 6 - #35 6 -#40- Arg Glu Ser Ala Lys Ser Glu Leu Thr Glu Se - #r# 650- (2) INFORMATION FOR SEQ ID NO:18:- (i) SEQUENCE CHARACTERISTICS:#acids (A) LENGTH: 23 amino (B) TYPE: amino acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear- (xi) SEQUENCE DESCRIPTION: SEQ ID NO:18:- Asp Leu Ile Glu Glu Ala Ala Ser Arg Pro Va - #l Asp Ala Val Ile# 15- Glu Gln Val Lys Ala Ala Gly Ala 20- (2) INFORMATION FOR SEQ ID NO:19:- (i) SEQUENCE CHARACTERISTICS:#pairs (A) LENGTH: 25 base (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear- (xi) SEQUENCE DESCRIPTION: SEQ ID NO:19:# 25 TCCA TGAGG- (2) INFORMATION FOR SEQ ID NO:20:- (i) SEQUENCE CHARACTERISTICS:#pairs (A) LENGTH: 30 base (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear- (xi) SEQUENCE DESCRIPTION: SEQ ID NO:20:# 30 TCTG TAGTTCTGAC- (2) INFORMATION FOR SEQ ID NO:21:- (i) SEQUENCE CHARACTERISTICS:#acids (A) LENGTH: 22 amino (B) TYPE: amino acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear- (xi) SEQUENCE DESCRIPTION: SEQ ID NO:21:- Phe Lys Lys Phe Phe Thr Gln Gly Trp Ala Gl - #y Trp Arg Lys Lys Thr# 15- Ser Phe Arg Lys Pro Lys 20- (2) INFORMATION FOR SEQ ID NO:22:- (i) SEQUENCE CHARACTERISTICS:#acids (A) LENGTH: 23 amino (B) TYPE: amino acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear- (xi) SEQUENCE DESCRIPTION: SEQ ID NO:22:- Pro Leu Lys Lys Leu Phe Thr Ser Thr Gly Le - #u Lys Lys Leu Ser Gly# 15- Lys Lys Gln Lys Gly Lys Arg 20- (2) INFORMATION FOR SEQ ID NO:23:- (i) SEQUENCE CHARACTERISTICS:#acids (A) LENGTH: 22 amino (B) TYPE: amino acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear- (xi) SEQUENCE DESCRIPTION: SEQ ID NO:23:- Lys Ala Ser Met Leu Cys Phe Lys Arg Arg Ly - #s Lys Ala Ala Lys Leu# 15- Ala Lys Pro Lys Ala Gly 20- (2) INFORMATION FOR SEQ ID NO:24:- (i) SEQUENCE CHARACTERISTICS:#acids (A) LENGTH: 9 amino (B) TYPE: amino acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear- (xi) SEQUENCE DESCRIPTION: SEQ ID NO:24:- Val Arg Lys Arg Thr Leu Arg Arg Leu1 5__________________________________________________________________________

Claims

1. A purified and isolated polynucleotide encoding a cAMP-dependent protein kinase (PKA)-binding polypeptide fragment of gravin (SEQ ID NO: 5).

2. The polynucleotide of claim 1 wherein the polypeptide fragment of gravin does not bind protein kinase C (PKC).

3. The polynucleotide of claim 2 encoding amino acid residues 1130-1780 of SEQ ID NO: 5.

4. The polynucleotide of claim 2 encoding amino acid residues 1130-1582of SEQ ID NO: 5.

5. The polynucleotide of claim 2 encoding amino acid residues 1526-1780 of SEQ ID NO: 5.

6. The polynucleotide of claim 2 encoding amino acids residues 1526-1582 of SEQ ID NO: 5.

7. The polynucleotide of claim 2 encoding amino acid residues 1537-1563 of SEQ ID NO: 5.

8. A purified and isolated polynucleotide encoding a protein kinase C (PKC)-binding polypeptide fragment of gravin (SEQ ID NO: 5).

9. The polynucleotide of clam 8 wherein the polypeptide fragment of gravin does not bind cAMP dependent protein kinase (PKA).

10. The polynucleotide of claim 9 encoding amino acid residues 265-556 of SEQ ID NO: 5.

11. The polynucleotide of claim 9 encoding amino acid residues 295-316 of SEQ ID NO: 5.

12. The polynucleotide of claim 9 encoding amino acid residues 514-536 of SEQ ID NO: 5.